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Interleukin-10 Deficiency Drives the Development of Mouse B cell Leukemia/Lymphoma 
Briana Fitch 
ABSTRACT 
 
Excessive inflammatory responses to common childhood infections are associated with 
an increased risk of pediatric B-cell Acute Lymphoblastic Leukemia (B-ALL).  Despite the 
identification of several neonatal inflammatory markers as B-ALL risk factors, the mechanism(s) 
by which these markers stimulate an excessive immune response leading B-ALL remain largely 
unknown.  Here, we demonstrate that IL-10 deficiency, a neonatal risk factor for B-ALL, 
indirectly impairs B lymphopoiesis and increases B cell DNA damage through induction of 
inflammation in mice.  Altered B cell number and DNA damage in Il10-/- mice were associated 
with a module of 6 pro-inflammatory/myeloid-associated cytokines (IL-1a, IL-6, IL-12p40, IL-13, 
CCL4/MIP-1b, and G-CSF).  Importantly, inflammation and defects in bone marrow B cells were 
attenuated by treating pre-leukemic Il10-/- Ckdn2a-/- mice with antibiotics that target Helicobacter 
species.  In the TEL-AML1 Ckdn2a-/- mouse model of B-ALL, decreased levels of IL-10 
accelerated B cell neoplasms in a dose dependent manner, and altered the mutational profile of 
B cell neoplasm to favor C>T and T>C mutations.  Infection of Cdkn2a-/- mice to Aspiculuris, a 
parasite that induces IL-10 production, delayed the development of B cell neoplasms in 
Cdkn2a-/- mice, demonstrating a novel protective effect of microbial exposure.  Our results 
identify commensal bacteria as modulators of bone marrow B cell responses to IL-10 deficiency, 
and suggest that microbial dysbiosis underlies the infectious etiology of pediatric B-ALL.  
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CHAPTER 1: INTRODUCTION 
1.1 INFECTIOUS ETIOLOGY OF PEDIATRIC B-ALL 
Although excessive inflammation in response to infection is a risk factor for pediatric 
B-cell Acute Lymphoblastic Leukemia (B-ALL), the underlying genetic and environmental 
causes of abnormal immune response have yet to be confirmed1–3.  The trend toward 
decreasing opportunities for microbial exposures in modern societies is commonly proposed as 
an underlying cause of abnormal inflammatory responses in the pathogenesis of ALL, as well as 
other childhood diseases including lymphoma, allergies, and asthma4,5.  Severe inflammation 
may provide pre-leukemic clones with the necessary environmental stimulation to acquire 
secondary driver mutations6.  One of the most common chromosomal translocations in pediatric 
ALL, ETV6-RUNX1 (also referred to as TEL-AML1), coordinates with infections to redirect the 
recombinase activity of RAG7.  The resulting RAG activity generates large deletions at off-target 
sites, ultimately aiding in the development of ALL7.  Mouse models have been paramount in 
identifying infectious stimuli that are capable of triggering this response in progenitor B cells.  
The list of infectious stimuli with this capacity ranges from lipopolysaccharide (LPS) to a host of 
infectious pathogens8,9.  It is now critically important to further understand whether this 
mechanism is relevant to the specific states of microbial and immune dysfunction that are risk 
factors in human pediatric B-ALL, as this may confirm targets for early interventions to prevent 
the development of this disease in children. 
1.2 ROLE OF IL-10 DEFICIENCY IN CANCER 
Neonatal deficiency in interleukin-10 (IL-10), a key cytokine in establishing early 
microbial homeostasis and immune tolerance to infection, is a strong predictor of childhood B 
cell malignancies10.  Children born with low levels of IL-10 have a 25-fold increased risk for 
developing ALL, whereas children with inherited IL10R deficiency have a high risk of developing 
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B-cell non-Hodgkin Lymphoma11,12.  IL-10 is a potent anti-inflammatory cytokine that suppresses 
myeloid cell activation, migration, and cytokine production by triggering downstream JAK/STAT 
signaling pathways13.  Very early onset of severe inflammatory bowel disorder (IBD) is observed 
in children born with IL-10 and IL-10R deficiency14.  Additionally, Il10-/- mice have been 
consistently used as a model system for IBD and colitis-associated colon cancer, in which 
bacterial infection and tumor promoting inflammation drive double stranded DNA breaks in 
intestinal cells15–17.  Although the gut is the primary site of inflammation in IL-10 deficient 
humans and mice, gut dysbiosis and inflammation can have distal genotoxic effects on 
peripheral blood lymphocytes that may contribute to extraintestinal hematological 
malignancies18.  Therefore, low IL-10 levels may be a source of excessive inflammation that 
drives B cell DNA damage during the development of childhood B cell leukemia/lymphoma. 
IL-10 also has B cell stimulatory properties, which may impact the development of 
childhood B cell malignancies in a cell-intrinsic manner that is independent of inflammation 
suppression.  B cell stress conditions that are induced by limited growth factors may have the 
capacity to exert a selective pressure on B cells that drives the acquisition of de novo mutations 
or provides a competitive advantage to pre-leukemic clones.  IL-10 is a B cell growth factor that 
enhances the survival and proliferation of B cell progenitors and mature B cells19,20.  Since B 
cells alternate between mutually exclusive stages of proliferation and recombination, decreased 
IL-10 levels may halt B cell proliferation and, as a result, prolong recombination and DNA 
damage21.  Alternatively, cytokine mediated B cell suppression may allow for the selection of 
pre-leukemic clones, as TGF-b has been demonstrated to disproportionately impair normal B 
cells relative to B cells expressing TEL-AML122.  The multiple cell-intrinsic and cell-extrinsic 
pathways in which IL-10 deficiency may impact B cell DNA damage have not been fully 
explored. 
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1.3 AIMS OF THIS STUDY 
We sought to identify what role IL-10 deficiency has, if any, in the development of 
childhood B cell malignancies.  Based on the epidemiological evidence linking low IL-10 levels 
and infections to childhood leukemia, we proposed that IL-10 deficiency increases the risk of 
childhood B cell leukemia/lymphoma by driving aberrant inflammatory responses to infectious 
stimuli.  To address this hypothesis, we crossed Il10-/- mice to our previously described 
TEL-AML1 Cdkn2a-/- model of pediatric B-ALL23. In addition to developing B-ALL, this model is 
also susceptible to B cell lymphomas and is responsive to environmental cues such as 
radiation23.  We report that IL-10 deficiency leads to increased DNA damage in bone marrow B 
cells as a result of inflammation.  Given the association between inflammation and microbial 
dysbiosis in Il10-/- mice24, these data are compatible with such dysbiosis being a source of DNA 
damage.  Survival studies demonstrate that IL-10 deficiency increases the aggressiveness of B 
cell disease, whereas pinworm exposure, known to elicit host IL-10 production25, is protective 
for leukemia/lymphoma. 
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CHAPTER 2:  INFLAMMATION IS ASSOCIATED WITH DISRUPTION OF B LYMPHOPOIESIS 
IN Il10-/- MICE 
2.1 INTRODUCTION 
The role of IL-10 in in vivo B cell development is controversial.  Although some studies 
suggest that Il10-/- mice have a deficit of B cells in the bone marrow26, others report normal B cell 
development24 in these mice.  This dilemma is furthered by the lack of investigations on B cell 
development in mice with IL-10 receptor (IL-10R) gene mutations.  A goal of the current study 
was to determine why in vivo IL-10 deficiency suppresses B cell development in particular 
circumstances. 
IL-10 can impact proliferation20,27 and differentiation28 of B cells, but these responses are 
influenced by the developmental stage and activation state of the B cells in culture.  In the case 
of B cell progenitors that have been isolated from murine bone marrow, early CD19- B cells have 
a proliferative response to recombinant murine IL-10 (rmIL-10), whereas the growth of slightly 
more differentiated CD19+ B cell progenitors is suppressed by rmIL-1019.  Another bi-directional 
effect of IL-10 is observed in mature B cells with different activation states.  During early activation, 
mature human IgM+ B cells are impaired by IL-10, however during late activation, these cells 
proliferate in response to IL-1020.  Therefore, in vivo studies that combine B cell subsets for 
analysis instead of resolving distinct B cell populations may not detect an effect of IL-10 deficiency 
on B cell development. 
In addition to the B-cell intrinsic properties of IL-10 described above, IL-10 also has B-cell 
extrinsic properties that may play a role in B cell development.  The only reports of altered B cell 
dynamics in Il10-/- mice have been conducted in the presence of spontaneous gut inflammation or 
colitis26.  Gut dysbiosis in Il10-/- mice and loss of IL-10 responsiveness in myeloid cells are each 
capable of driving the unregulated differentiation of splenic transitional B cells into marginal zone 
B cells24.  The myeloid response that occurs in Il10-/- mice is typically characterized by an 
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increased presence of granulocytes, and pro-inflammatory cytokines24,29.  Increased myeloid cell 
activation and/or production may contribute to the inflammatory state of Il10-/- mice.  Interestingly, 
both inflammation and myeloid cell production are associated with suppression of B cell 
development30.  Whether myeloid growth factors or pro-inflammatory cytokines actively suppress 
B cell development in Il10-/- mice remains largely unknown.  
The question that we aimed to address is whether the impairment of B cell development 
in Il10-/- mice is influenced by a B-cell intrinsic or B-cell extrinsic mechanism.  Given that B-cell 
extrinsic myeloid responses drive B cell loss and are prominent in Il10-/- mice, we hypothesized 
that the loss of B cells in Il10-/- mice is correlated with increased abundance of myeloid cells and 
myeloid-associated cytokines.  Our approach to defining the relationship between B cell 
development and myeloid inflammation in Il10-/- mice was to perform a comprehensive analysis 
of different B cell subsets across the lymphoid tissues of Il10-/- mice displaying variable levels of 
inflammation and wild-type mice with no inflammation.  Our results indicate that B cell loss in Il10-
/- mice is most profound in the pre-B cell population and that the cytokines G-CSF and IL-12p40 
may play a role in this B cell deficit. 
 
2.2 RESULTS 
2.2.i Hematopoiesis is altered in Il10-/- mice  
We first sought to determine whether Il10-/- mice in our colony had reduced levels of bone 
marrow B cells relative to wild-type controls.  Il10-/- mice that have been housed under SPF 
conditions can spontaneously develop an inflammatory response that is characterized by an early 
expansion of cytokine-producing macrophages and CD4+ Th1 cells in the gut29.  The severity of 
inflammation in Il10-/- mice is influenced by mouse husbandry conditions within an animal facility 
and genetic background.  In regard to genetic background, the strongest inflammatory responses 
have been observed on the C3H/HeJBir and 129/Sv backgrounds.  Il10-/- mice on the 129/SvEv 
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develop enterocolitis and have been used to model Crohn’s Disease31.  Intermediate inflammatory 
responses are present in BALB/cJ and NOD/Lt  mice and mild inflammation has been reported 
on the C57BL/10 and C57BL/6J genetic bakcgrounds32,33.   
We had a particular interest in examining patterns of inflammation on the FVB/N 
background because it is commonly used in genetically engineered cancer models, including our 
model of TEL-AML1 B-cell Acute Lymphoblastic Leukemia (B-ALL)23.  Inflammation in Il10-/- mice 
on the FVB/n background had not been previously described and the genetic variants that 
promote inflammation in Il10-/- mice have yet to be reported.  Therefore, it was unclear whether 
the FVB/n genetic background would be permissive for the development of spontaneous 
inflammatory responses in Il10-/- mice that were housed in our SPF facility.  We observed 
indications of IL-10 deficiency induced colitic lesions, including diarrhea and rectal prolapse, in a 
subset of 8-week-old Il10-/- mice on the FVB/n background, herein referred to as Il10-/- mice.  We 
therefore selected an age range of 8-12 weeks-old to determine whether there was additional 
evidence of inflammation or B cell disruption in Il10-/- mice.  To this end, myeloid and lymphoid 
lineages were enumerated in the bone marrow, spleen, and peripheral blood of age- and sex-
matched wild-type and Il10-/- mice.  We observed that Il10-/- mice had an increased count of 
CD11b+ CD19- myeloid cells across each of the three lymphoid tissues that were surveyed, but 
had decreased counts of CD19+ B cells in the bone marrow and blood (Figure 2.1A).  This loss 
of B cells did not extend to the spleen, suggesting that Il10-/- mice may have a compensatory 
mechanism of B cell expansion in secondary lymphoid organs.  The numbers of CD3+ T cells 
were not significantly altered by IL-10 loss.  These results indicate that myeloid and B cell lineages 
are specifically impacted by IL-10 loss in mice on the FVB/n background.  
To investigate the impact of IL-10 loss on B lymphopoiesis, we used flow cytometry to 
identify the following subsets of CD19+ B220+ B cells in the bone marrow of adult mice: pro-B 
cells (CD43+ IgD- IgM-), pre-B cells (CD43- IgD- IgM-), IgM+ Immature B cells (IgM+ IgD-), and 
mature recirculating (MR) B cells (IgD+ IgM+).  Strikingly, the decrease in B cells in Il10-/- mice 
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was almost exclusively in the pre-B cell population, which was abundant in control FVB/n mice 
(Figure 2.1B).  MR B cells were also significantly decreased in the bone marrow Il10-/- mice.  The 
drastic reduction in pre-B cells resulted in a relative increase in the percent of pro-B and IgM+ B 
cells within the CD19+ B220+ bone marrow B cell population (Figure 2.1C).  We did not detect a 
decrease in pro-B or IgM+ B cells in Il10-/- mice; however, these B cell populations are far less 
abundant in adult mice than pre-B cells.  We also performed parallel analyses in young 4-6-week-
old mice and found that young Il10-/- mice had a significant decrease in the percent of B1 
progenitors, pre-pro B (B2 progenitors), pro-B, pre-B, IgM+ Immature B, transitional B, and MR B 
cells compared to FVB/n controls (Figure 2.2A).  Therefore, IL-10 deficiency in mice on the FVB/n 
background can result a loss of the major B cell subsets in pups and a less expansive loss in pre-
B and MR B cells in adult mice.  
Inflammation has a well described capacity for directing the hematopoietic output of the 
bone marrow to favor neutrophil production at the expense of B cell development30,34.  We 
hypothesized that neutrophils would be the predominant myeloid population that was expanded 
in Il10-/- mice.  Gr1+ neutrophil and Gr1- monocyte subpopulations of CD11b+ CD19- myeloid 
cells were measured by flow cytometry and the absolute count was calculated based on the CBC 
white blood cell count.  We observed increased neutrophil and monocyte counts in the bone 
marrow, blood, and spleen of Il10-/- mice relative to controls (Figure 2.1D).  Together, these data 
show that myeloid cell expansion occurs concurrently with B cell deficiency in our colony of Il10-/- 
mice.  
 
2.2.ii Myeloid-derived cytokines in Il10-/- mice are associated with B cell loss 
We next investigated the potential impact of inflammation on B cell numbers in Il10-/- mice.  
IL-10 has an important role in promoting Th2 immunity35–37 and suppressing Th1 and myeloid-
related immune responses38–40.  In previous work, Il10-/- mice with inflammation demonstrated a 
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bias toward Th1 immunity, as demonstrated by increased levels of IL-1a, IL-6, TNF-a, and IFN-g 
in the colon29.  To determine whether a similar immune response was present in the blood of Il10-/- 
mice, we measured the concentration of 32 cytokines that are involved in Th1, Th2, Th17, and 
innate immune responses.  Of the 32 cytokines profiled, 6 were significantly increased in Il10-/- 
mice (adjusted p-value < 0.05), whereas significant decreases in cytokine levels were not 
detected (Table 2.1).  Surprisingly, Il10-/- plasma did not have increased expression of the 
Th1-related cytokines IFN-g and TNF-a.  Notably, G-CSF levels in Il10-/- mice showed a 46-fold 
increase in median concentration relative to control mice (Table 2.1).  Additional myeloid growth 
factors, including IL-3 and M-CSF41, were elevated in the blood of Il10-/- mice, as well as the 
pro-inflammatory cytokines IL-1a, IL-6, and MIP-1b (CCL4) (Figure 2.1E).  Cytokines that bridge 
the innate and adaptive immune responses, such as IL-12p40, IL-13, and IL-17A42–45, were also 
expressed at higher levels in Il10-/- mice (Figure 2.1E).  These data demonstrate that myeloid 
growth factors and pro-inflammatory cytokines predominated the peripheral blood inflammatory 
response in Il10-/- mice.  
To identify which inflammatory cytokines may contribute to the reduction of bone marrow 
B cells in Il10-/- mice, we first used Pearson correlation to determine the association between 
selected cytokines and the abundance of different B cell populations.  Of the cytokines that were 
elevated in Il10-/- mice, G-CSF and IL-3 have been reported to suppress murine B cell 
progenitors46–49.  Increased levels of IL-3, but not G-CSF, were significantly correlated with 
decreased pre-B cell numbers in Il10-/- mice (Figure 2.1F). Of note, the increased percent of 
neutrophils within the bone marrow of Il10-/- mice was also associated with reduced pre-B cell 
numbers (Figure 2.1G), supporting a role of myelopoiesis in the disruption of B cell development.  
Linear regression was then used to further examine whether increased cytokine 
production was predictive of B cell or myeloid findings in Il10-/- mice.  Regression analyses was 
first performed on flow cytometry data and absolute levels of all 32 measured cytokines.  P-values 
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were adjusted using the Bonferroni-Holm method to obtain the family-wise error rate (FWER).  
The cutoff for significance was FWER < 0.05.  G-CSF and IL-12p40 were both significantly 
correlated with decreased counts of pre-B and MR B cells (Table 2.2). In contrast, G-CSF 
correlated with increased peripheral blood neutrophils and IL-12p40 correlated with increased 
bone marrow monocytes.  These results are consistent with previous reports in which G-CSF 
treatment shifted the hematopoietic output of murine bone marrow to favor neutrophil production 
by depleting pre-B cells34.  These data also suggest that IL-12 may be involved in an analogous 
mechanism in which monocyte production is favored at the expense of pre-B cells and MR B cells.  
Taken together, our analyses of cytokines revealed that the pro-inflammatory cytokines IL-3, 
G-CSF, and IL-12p40 were associated with the loss of B cells in the bone marrow of Il10-/- mice.  
A limitation of using absolute cytokine concentrations for analysis is that information on 
relative changes in cytokine levels is missed. This is of particular importance when analyzing 
samples with inflammation, a process that could increase the concentration of several cytokines.  
We found that, in regard to absolute concentration, most cytokines in our dataset were positively 
correlated with each other (Figure 2.3A) and with the mean cytokine concentration in each 
sample (Figure 2.3B).  We therefore decided to use a previously described approach for 
calculating an adjusted cytokine concentration that takes into account the overall cytokine 
concentration within each sample50.  Although some cytokine correlations differed after cytokine 
adjustment, G-CSF and IL-12p40 were correlated with each other before and after adjustment 
(Figure 2.3C).  We then repeated our linear regression analysis, this time substituting adjusted 
cytokine levels for absolute cytokine concentrations. We observed that, after adjustment, G-CSF 
and IL-12p40 were still the only cytokines that had a significant association with decreased 
numbers of bone marrow pre-B cells and MR B cells (Table 2.3). This analysis further strengthens 
our conclusion that inflammation is associated with B cell loss in Il10-/- mice. 
We then evaluated potential mechanisms by which myeloid growth factors and 
pro-inflammatory cytokines may mediate a reduction of bone marrow B cells in Il10-/- mice, starting 
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with extramedullary hematopoiesis.  G-CSF treatment can displace hematopoietic progenitors 
and B cells from their local niche in the bone marrow to the periphery51.  We assessed whether 
the site of B lymphopoiesis was relocated from the bone marrow to the periphery in Il10-/- mice by 
measuring the total cellularity and number of hematopoietic progenitors in the bone marrow, 
blood, and spleen.  Despite observing an increase in the spleen/body weight ratio (Figure 2.2B) 
and spleen cellularity (Figure 2.2C), only a modest displacement of LSKs and CLPs was 
observed in Il10-/- mice (Figure 2.2D).  The myeloid expansion that we observed in the spleen 
likely accounts for increased cellularity and weight of the spleen in Il10-/- mice.  A greater percent 
of HSCs and CLPs were proliferating in Il10-/- mice, but the level of proliferation was similar 
between tissues (data not shown), suggesting that bone marrow progenitors in Il10-/- mice do not 
have a lower proliferative capacity than progenitors in other lymphoid tissues.  It is possible that 
extramedullary niches may be more permissive for the development or survival of B cells than the 
inflamed bone marrow.  If this were the case, then peripheral lymphoid tissues in Il10-/- mice would 
be expected to have more B cells than FVB/N mice.  However, we found a decreased number of 
B cells in the blood and spleen of Il10-/- mice (Figure 2.1B).  These data are not consistent with 
a role of extramedullary hematopoiesis or B cell mobilization in reducing the presence of B cells 
in Il10-/- bone marrow.   
2.2.iii IL-10 deficiency contributes to pathways of B cell transformation 
To investigate the role of IL-10 deficiency in pathways of B cell transformation, we focused 
on DNA damage, as others have described an increased presence of RAG-mediated mutations 
in models of B-ALL that are driven by infectious stimuli8,52.  Inflammation-associated DNA damage 
is also induced in small intestinal cells and peripheral blood T cells of Il10-/- mice.  There is limited 
characterization of peripheral blood B cell DNA damage in Il10-/- mice and these studies have not 
reported DNA damage in the bone marrow B cell compartment.  We asked whether B cells carry 
a higher level of DNA damage in Il10-/- mice than in FVB/n controls.  Given that RAG activity and 
 11 
inflammatory factors in mice can induce double stranded DNA breaks (DSBs) in immunoglobulin 
(Ig) and non-Ig genes8, we proposed that IL-10 deficiency-induced inflammation might increase 
the percent of bone marrow B cells with DSBs.  To identify B cells with DSBs we used flow 
cytometry to measure γH2AX, a DNA repair protein which responds rapidly to DSBs.  In Il10-/- 
mice, the percent of γH2AX+ cells was significantly increased in bone marrow B cells relative to 
FVB/n controls (Figure 2.4A).  We expected pre-B cells to have the highest percent of DNA 
damage among bone marrow B cell populations because pre-B cells have high intrinsic levels of 
RAG and experience more suppression in our Il10-/- mice than other B cell populations.  In two 
independent experiments using at least 5 mice per group, analysis of γH2AX expression among 
B cell subsets revealed that an increased percent of pro-B cells and IgM+ immature B cells 
expressed γH2AX in Il10-/- mice (Figure 2.4B).  This result was not representative of a third 
replicated experiment; however it is feasible that pro-B and IgM+ B cells would have the capacity 
for increased RAG-mediated mutagenesis, as endogenous RAG regulates VDJ recombination 
and receptor editing in these populations.  Taken together, our results demonstrate that IL-10 loss 
severely restricts B cell development in the bone marrow and promotes DNA DSBs in the few 
remaining B cells.  
To directly assess the impact of IL-10 loss on in vivo B cell proliferation, we injected BrdU 
into Il10-/- and FVB/n mice, then collected bone marrow for analysis 1 hour later.  Inflammation in 
aged mice has been associated with reduced pro-B cell proliferation53, therefore we expected B 
cell progenitors in Il10-/- mice to have decreased levels of proliferation.  Surprisingly, loss of IL-10 
resulted in increased proliferation in bone marrow B cells (Figure 2.4C) with no detectable 
proliferative advantage in any particular B cell subset (Figure 2.4D).  This suggests that the 
absence of IL-10 provides some B cells with a proliferative advantage, possibly by exerting a 
selective pressure that drives the acquisition of favorable mutations.  Overall, our results provide 
evidence that IL-10 deficiency negatively selects against B cells and drives a subset of B cells to 
acquire DNA damage and proliferate.  
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2.2.iv Myeloid inflammation in Il10-/- mice is associated with B cell DNA damage  
Given the association between inflammatory markers and human pediatric ALL, we were 
interested in testing whether properties of B cell transformation, such as DNA damage and 
hyperproliferation, were correlated with cytokine levels in Il10-/- mice. Linear regression analysis 
did not reveal any significant associations between individual cytokines and B cell DNA damage 
or proliferation.  However, during complex immune responses such as inflammation, cytokines 
may change in groups.  Clustering analysis is an appropriate approach for identifying patterns of 
cytokine expression that are associated with disease symptoms or outcomes.  We therefore 
decided to apply clustering analysis to our cytokine dataset to determine whether cytokine clusters 
were more significantly associated with B cell DNA damage and proliferation than individual 
cytokines.  To this end we used CytoMod50, an unsupervised approach to clustering absolute and 
adjusted levels of cytokines across individuals.  We then used linear regression to determine 
whether there was an association between cytokine modules and altered B cell DNA damage or 
proliferation. Of the 3 absolute cytokine modules that were identified in our cohort of FVB/n and 
Il10-/- mice (Figure 2.5A), none were associated with changes in B cell number, DNA damage, or 
proliferation. However, of the 5 adjusted cytokine modules (Figure 2.5B), plasma module 5 (PM5) 
was associated with an increased percent of DNA damage in bone marrow B cells and decreased 
numbers of pre-B and MR B cells (Table 2.5). The adjusted module PM5 contained the following 
cytokines: IL-1a, IL-6, IL-12p40, IL-13, G-CSF, and MIP-1b (Figure 2.5B).  Multiple KEGG 
pathways were significantly associated with PM5 including cytokine-cytokine receptor interaction, 
IBD, and the Jak-STAT signaling pathway (data not shown). However, none of these pathways 
were unique to the PM5 module. These data ultimately demonstrate that the combination of 
cytokines in the PM5 module is more strongly associated with B cell DNA damage in Il10-/- mice 
than any individual cytokine that was measured.  These results provide further evidence that 
inflammation in Il10-/- mice is associated with B cell deficiency and DNA damage.  A valuable 
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question for future studies is whether identifying cytokine modules in newborns would be a useful 
approach for predicting levels of B cell DNA damage or B-ALL risk in humans. 
 
2.3 DISCUSSION 
Our data demonstrate that IL-10 deficiency can increase neutrophil and monocyte output 
while also decreasing the number of B cells in the bone marrow.  Therefore, it is possible that 
IL-10 plays opposing roles in myelopoiesis and B lymphopoiesis.  We aimed to understand 
whether the role of IL-10 in hematopoiesis was mediated directly through a loss of IL-10 
production in myeloid and B cells or indirectly through a change in the bone marrow 
microenvironment.  We found evidence for an indirect mechanism, as the drastic changes in 
myeloid and B cell abundance in Il10-/- mice were associated with the myeloid-derived 
pro-inflammatory cytokines G-CSF and IL-12p40.  G-CSF has a well-established function in 
neutrophil production and pre-B cell suppression; therefore, it was not surprising that we found 
high G-CSF levels to be associated with myeloid expansion and B cell deficiency.  Our results 
imply that B cell loss in Il10-/- mice was driven by pro-inflammatory cytokines.  It is therefore 
possible that the impact of IL-10 loss on B cell development may have been missed in studies 
that analyzed Il10-/- mice in the absence of inflammation.  
In contrast to numerous in vitro studies which show that recombinant IL-10 can function 
as a growth factor that directly stimulates or suppresses isolated B cells, our findings suggest that 
endogenous IL-10 may not be required for the maintenance of in vivo B cell homeostasis.  This 
does not rule out the possibility that bone marrow B cells may become dependent on IL-10 
signaling during an inflammatory response.  IL-10 can stimulate B cell survival by activating the 
Bcl-2 anti-apoptotic pathway54, thus B cell apoptosis could be a consequence of decreased IL-10 
signaling in the context of inflammation.  Interestingly, dysregulation of splenic marginal zone B 
cells in Il10-/- mice has been attributed to a loss of IL-10 signaling in myeloid cells, but not B cells24.  
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It would be useful to determine whether a loss of IL-10 signaling in B cells is responsible for B cell 
suppression in Il10-/- mice.  One approach to directly addressing this question would be to 
investigate B cell development in mice with a tissue-specific knockout of IL-10R in B cells.  
Alternatively, comparative analysis of wild-type and Il10ra-/- B cells after transplantation into 
Il10-/- mice with inflammation could also provide insight into the role of IL-10 signaling in B cell 
development.   
Our work also revealed that the earliest B cell subset that is decreased in Il10-/- mice varies 
by age.  Pre-B cells were the only B cell progenitor population that was decreased in adult Il10-/- 
mice, whereas pre-pro B, pro-B, and pre-B cells were each reduced in young Il10-/- mice.  This 
difference may reflect the relatively low number of pre-pro and pro-B cells in the bone marrow of 
adult wild-type mice.  Notably, IL-10 loss in young and adult mice did not decrease the number of 
common lymphoid progenitors (CLPs), which possess T and B cell differentiation potential under 
physiologic conditions.  Since CLPs can differentiate into dendritic cells under inflammatory 
conditions55, it is possible that inflammation in Il10-/- mice biased the differentiation potential of 
CLPs away from the B cell lineage in favor of dendritic cell production.  In vitro analysis of the 
multilineage differentiation capacity of CLPs isolated from wild-type and Il10-/- mice could be 
useful in determining the effect of IL-10 deficiency on the capacity of CLPs to differentiate into 
committed B cell progenitors.  
The slight increase in HSCs and CLPs that we observed in the spleen of Il10-/- mice raises 
the possibility that extramedullary B lymphopoiesis compensates for the profound loss of B cell 
progenitors in the bone marrow.  One approach for demonstrating increased B lymphopoiesis 
outside of the bone marrow of Il10-/- mice would be to find evidence for an increased number of B 
cell progenitors in the periphery.  However, we did not detect an increase in pro-B or pre-B cells 
in the blood or spleen of Il10-/- mice.  When attempting to detect pre-B cells in the periphery, we 
looked to identify B cells with an IgK- immunophenotype.  In the bone marrow, the IgK- population 
is largely composed of two B cell subsets: CD43+ pro-B cells and CD43- pre-B cells.  In contrast, 
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peripheral lymphoid organs house additional subsets of IgK- B cells, including mature B cells that 
that have lost surface immunoglobulin expression during differentiation into plasma cells.  The 
increased number of IgK- B cell populations can present a challenge to detecting pre-B cells in 
the periphery.  Based on the antibody panel that was used in this study, we cannot distinguish 
pre-B cells from mature IgK- B cell populations.  That being said, there was no expansion in IgK- 
B cells in the periphery, suggesting that the pre-B cells that were lost from the bone marrow did 
not move into other tissues.   
Our analysis of DNA damage across different B cells populations in Il10-/- mice revealed 
that, in particular experiments, pro-B cells and IgM+ B cells carried elevated levels of DNA 
damage.  Notably, this pattern was not present in pre-B-cells.  This may reflect the massive loss 
of pre-B cells in the bone marrow of Il10-/- mice, an acquisition of non-DSB DNA damage in pre-B 
cells, or different susceptibilities to DSBs among B cell populations during inflammation.  The 
latter mechanism is supported by our observation that IgM+ B cells had the highest level of DNA 
damage and were the only B cell population to display increased proliferation in Il10-/- mice.  It is 
interesting to consider that the increased proliferation of IgM+ B cells could be a compensatory 
response that is triggered by the loss of pre-B cells.  Error-prone DNA replication is a possible 
consequence of such lymphocyte hyperproliferation in the context of inflammation.  Additionally, 
human B cell subsets differ in endogenous expression of RAG and AID enzymes56,57, which are 
capable of driving B cells mutagenesis when concurrently expressed.  Exome sequencing or 
targeted VH region sequencing could be useful in determining whether the mutagenic processes 
in Il10-/- mice differ between pro-B cells and IgM+ B cells. 
In regard to disease relevance, our work presents a feasible mechanism for the 
epidemiological findings that decreased levels of IL-10 in newborns are associated with an 
increased risk of pediatric B-ALL11.  Common infections, as opposed to a specific pathogen, are 
believed to contribute to pediatric B-ALL.  To elucidate the paradigm of how common infectious 
exposures impact B cell mutagenesis, previous studies have stimulated B cells or the murine 
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immune system with TLR agonists8 or a set of pathogenic exposures9,58.  Our approach is 
distinguished by perturbing the mouse immune system in mice to reflect a specific immune defect 
that has been observed in humans with high ALL risk.  Here, we report that B cell DNA damage 
in Il10-/- mice coincides with a set of pro-inflammatory cytokines that are associated with 
inflammatory bowel disease (IBD). Given that microbial dysbiosis is associated with the 
dysregulated immune response of IBD, our finding suggests that microbial dysbiosis may mediate 
B cell DNA damage, and possibly leukemogenesis, in the absence of IL-10.  This interpretation 
is supported by numerous studies correlating newborn gut dysbiosis to childhood ALL risk59.  It 
may be useful to classify the bacterial species that are associated with B cell DNA damage and 
ALL risk in future studies. 
Another advantage of our approach was crossing the IL-10 deletion onto the FVB/n strain, 
which is a genetic background that has been commonly used to engineer mouse models of 
cancer.  Previous studies have used Il10-/- FVB/n mice to understand the protective role of IL-10 
in solid tumors60,61.  Propagation of tumor promoting inflammation and impairment of tumor 
immune surveillance are cancer pathways that have been attributed to the loss of IL-10 in solid 
tumor mouse models.  Few studies have used Il10-/- FVB/n mice to explore the role of IL-10 in 
hematological malignancies.  Here, we identified pathways of B cell disease in the bone marrow 
of Il10-/- mice with inflammation.  Altered B cell abundance, proliferation, and DNA damage were 
all heightened in Il10-/- mice that were not genetically engineered to express leukemic mutations.  
Overall, our data suggest that IL-10 protects the bone marrow microenvironment from giving rise 
to B cells with pre-leukemic properties.  IL-10 therapy or treatment with immunosuppressive 
agents may therefore be beneficial approaches for decreasing ALL risk in children prone to 
aberrant immune responses to infection.  
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2.4 FIGURES
 
Figure 2.1. Disruption of hematopoiesis in Il10-/- mice is correlated with neutrophilic 
inflammation. 
Analysis immune cell lineages and cytokines in 8-12 week-old FVB/n and Il10-/- mice.  (A) 
Number of CD19+ B, CD3+ T, and CD11b+ CD19- myeloid cells in the bone marrow, blood, and 
spleen.  (B) Number of pro-B cells (B220+ CD19+ IgM- IgD- CD43+), pre-B cells (B220+ CD19+ 
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IgM- IgD- CD43-), IgM+ immature B cells (B220+ CD19+ IgM+ IgD-), and mature recirculating (MR) 
B cells (B220+ CD19+ IgM+ IgD+) in the bone marrow.  (C) Percent of B cell subsets in B220+ 
CD19+ bone marrow.  (D) Number of neutrophils (CD11b+ CD19- Gr1hi Ly6Clo) and monocytes 
(CD11b+ CD19- Gr1lo Ly6Chi) in the bone marrow, blood, and spleen.  (E) Absolute plasma 
concentrations of a selected panel of myeloid, pro-inflammatory, and T-cell regulatory cytokines 
detected by a bead-based multiplex Luminex assay.  (F) Correlation between number of pre-B 
cells in the bone marrow and plasma concentration of IL-3 or (G) percent of neutrophils in the 
bone marrow of Il10-/- mice.  Bar graph data show mean ± SD.  Nominal p-values are 
represented.  *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.001.   
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Figure 2.2. Distribution of hematopoietic stem and progenitor cells is altered in young 
Il10-/- mice. 
Analysis of 4-6 week-old FVB/n and Il10-/- mice.  (A) Percent of CLP (Lin-, IL7-R+ , C-kitlo, Sca-
1lo), B1 progenitors “B1” (Lin-, CD93+ B220- CD19+), pre-pro B cells/B2 progenitors “B2” (Lin-, 
CD93+ B220+ CD19- CD43+), pro-B cells (B220+ CD19+ IgM- IgD- CD43+), pre-B cells (B220+ 
CD19+ IgM- IgD- CD43-), IgM+ immature B cells (B220+ CD19+ IgM+ IgD-), transitional B cells 
(B220+ CD19+ IgM+ IgDlo), and mature recirculating (MR) B cells (B220+ CD19+ IgM+ IgD+) of 
total live bone marrow cells.  (B) Ratio of spleen to body weight and gross morphology of 
spleen.  (C) Spleen cellularity.  (D) Number Lin- LSK (Lin- C-kit+ Sca-1+) CMP (Lin-, C-kit+ , Sca-
1-, CD34+ , FcgR-), GMP (Lin-, C-kit+ , Sca-1-, CD34+ , FcgR+), MEP (Lin-, C-kit+ , Sca-1-, CD34-, 
FcgR-), CLP (markers listed under A) in the bone marrow.  Bar graph data show mean ± SD.  *p 
≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.001. 
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Figure 2.3. Cytokine levels in combined dataset of FVB/n and Il10-/- mice. 
(A) Hierarchical clustering of Pairwise Pearson’s correlations among absolute cytokine levels.  
(B) Correlation between individual cytokine level and mean concentration of all cytokines for 
each sample.  (C) Hierarchical clustering among adjusted cytokine levels 
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Figure 2.4. Bone marrow B cells in Il10-/- mice have increased DNA damage and 
proliferation. 
Analysis of 8-12 week-old FVB/n and Il10-/- mice.   Percent of H2AX+ cells among (A) Total 
bone marrow B cells and (B) Bone marrow B cell subsets.   Percent of BrdU+ cells among (C) 
Total bone marrow B cells and (D) Bone marrow B cell subsets.   Bar graph data show mean ± 
SD.   *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.001.   
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Figure 2.5. Cytokine modules defined in combined cytokine profiles of FVB/n and Il10-/- 
mice. 
Heatmap of cytokine modules displaying pairwise reliability scores of (A) Absolute and (B) 
Adjusted cytokines over 1,000 random samplings of subjects.  The optimal number of clusters 
was determined by the Tibshirani gap statistic method.   
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2.5 TABLES 
 
Table 2.1. Univariate analysis comparing cytokine profiles of 6 FVB/n controls and 10 
Il10-/- mice. 
 
Cytokine
FVB/n Median 
(pg/ml)
Il10 -/- Median 
(pg/ml)
Nominal 
p-value
Corrected 
p-value
Fold Change 
(relative to 
control)
IL-1a 11.19 50.06 7.094E-07 2.270E-05 4.48
IL12p40 710.07 2953.65 3.705E-06 0.0001 4.16
G-CSF 119.80 5738.25 4.653E-06 0.0001 47.90
IL-6 12.21 131.50 0.0002 0.0056 10.77
MIP-1B 8.14 37.47 0.0003 0.0098 4.60
IL-17A 20.71 46.49 0.0011 0.0349 2.24
M-CSF 5945.67 7082.69 0.0017 0.0545 1.19
IL-13 37.17 238.62 0.0039 0.1260 6.42
RANTES 64.04 180.56 0.0058 0.1861 2.82
IL-3 3.32 6.54 0.0381 1.2186 1.97
Eotaxin 568.11 812.23 0.0962 3.0783 1.43
KC 60.61 286.56 0.1035 3.3122 4.73
MIG 314.23 507.64 0.1903 6.0886 1.62
VEGF 103.58 112.79 0.1906 6.0987 1.09
GM-CSF 137.65 183.49 0.2481 7.9377 1.33
IL-2 34.25 48.70 0.2585 8.2715 1.42
IL1b 4.56 8.01 0.3035 9.7117 1.76
IL-10 10.28 22.86 0.3236 10.3552 2.22
PDGF-BB 2413.06 2494.89 0.3463 11.0805 1.03
TNFα 32.35 47.65 0.3571 11.4271 1.47
MIP-1a 8.07 8.92 0.3715 11.8874 1.11
MIP-2 13.52 23.12 0.4077 13.0463 1.71
LIF 357.17 327.99 0.4342 13.8933 0.92
IL-4 6.32 5.98 0.4403 14.0902 0.95
IL-5 18.62 26.32 0.4426 14.1636 1.41
IL-18 256.09 59.91 0.4564 14.6057 0.23
IFNγ 40.10 51.32 0.4734 15.1486 1.28
IL-15 2371.44 2851.94 0.4985 15.9534 1.20
IL-9 24.49 26.31 0.6781 21.7002 1.07
MCP-1 569.99 665.52 0.7017 22.4540 1.17
Basic FGF 160.09 159.87 0.8299 26.5580 1.00
IL-12p70 70.71 85.91 0.9682 30.9819 1.21
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Table 2.2. Absolute plasma cytokine associations with immune cell phenotypes 
  
Outcome Module/Analyte Coef P-value FWER FDR
PBMonosCount IL-17A 0.5843 1.31E-06 4.19E-04 3.55E-04
AbsMRCount IL12p40 -3.4133 2.22E-06 7.08E-04 3.55E-04
AbsPreBCount G-CSF -13.2357 5.41E-06 0.0017 4.44E-04
AbsBCount G-CSF -18.4784 5.91E-06 0.0019 4.44E-04
AbsMRCount G-CSF -3.3445 6.93E-06 0.0022 4.44E-04
AbsBCount IL12p40 -18.0805 1.71E-05 0.0054 9.03E-04
BMMonosCount IL12p40 0.0551 1.99E-05 0.0063 9.03E-04
PBNeutsCount IL-6 2.8140 2.48E-05 0.0078 9.03E-04
AbsPreBCount IL12p40 -12.8124 2.54E-05 0.0079 9.03E-04
PBMonosCount IL-1a 0.2734 9.53E-05 0.0296 0.0030
PBNeutsCount G-CSF 1.9312 1.69E-04 0.0525 0.0049
PBMonosCount IL12p40 0.2021 1.95E-04 0.0604 0.0052
BcellH2AX G-CSF 2.9753 3.09E-04 0.0952 0.0076
PBNeutsCount IL-1a 2.4503 4.36E-04 0.1339 0.0100
BMMonosCount M-CSF 0.0494 6.31E-04 0.1932 0.0135
BcellH2AX MIP-1B 2.8400 9.35E-04 0.2852 0.0187
AbsPreBCount M-CSF -11.2483 0.0011 0.3451 0.0213
PBMonosCount G-CSF 0.1955 0.0012 0.3625 0.0213
PBMonosCount IL-6 0.2699 0.0018 0.5339 0.0287
AbsBCount M-CSF -15.3550 0.0018 0.5408 0.0287
BcellH2AX IL-1a 2.7387 0.0019 0.5662 0.0288
ProBH2AX RANTES 4.0118 0.0021 0.6143 0.0298
ProBH2AX MIP-1B 4.0022 0.0021 0.6380 0.0298
BMMonosCount G-CSF 0.0462 0.0024 0.7112 0.0319
AbsPreBCount MIP-1B -10.7500 0.0026 0.7648 0.0321
PBNeutsCount MIP-1B 1.3723 0.0026 0.7697 0.0321
AbsBCount MIP-1B -14.9896 0.0027 0.7964 0.0321
PBNeutsCount IL-17A 4.5575 0.0031 0.8960 0.0349
ImmatureBH2AX RANTES 5.0754 0.0044 1 0.0481
AbsMRCount MIP-1B -2.6249 0.0047 1 0.0491
PBMonosCount RANTES 0.1708 0.0048 1 0.0491
Continued on next page
Table 2: Absolute plasma cytokine associations with immune cell phenotypes
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Outcome Module/Analyte Coef P-value FWER FDR
AbsMRCount M-CSF -2.6147 0.0049 1 0.0491
BcellH2AX IL12p40 2.5669 0.0051 1 0.0499
PBNeutsCount IL12p40 1.6431 0.0062 1 0.0577
BMNeutsCount IL12p40 0.2751 0.0063 1 0.0577
AbsMRCount IL-1a -2.5518 0.0067 1 0.0600
PBMonosCount MIP-1B 0.1380 0.0083 1 0.0720
ImmatureBH2AX IL-1a 4.7662 0.0096 1 0.0808
ImmatureBH2AX G-CSF 4.7213 0.0106 1 0.0873
AbsBCount IL-1a -13.3418 0.0122 1 0.0950
BMMonosCount Eotaxin 0.0408 0.0122 1 0.0950
AbsPreBCount IL-1a -9.4468 0.0134 1 0.1009
PBMonosCount Eotaxin 0.1348 0.0136 1 0.1009
ImmatureBH2AX IL-13 4.5640 0.0150 1 0.1091
BcellH2AX IL-13 2.3073 0.0169 1 0.1199
AbsPreBCount IL-6 -9.0828 0.0194 1 0.1328
BMMonosCount IL-1a 0.0388 0.0195 1 0.1328
ProBH2AX IL-1a 3.3243 0.0204 1 0.1358
AbsBCount IL-6 -12.4547 0.0229 1 0.1466
BMMonosCount MIP-1B 0.0381 0.0229 1 0.1466
BcellH2AX IL-6 2.2181 0.0237 1 0.1485
ImmatureBH2AX MIP-1B 4.3016 0.0251 1 0.1543
AbsMRCount IL-6 -2.2033 0.0280 1 0.1647
AbsBCount IL-13 -12.1021 0.0286 1 0.1647
ImmatureBH2AX MIP-2 4.2265 0.0287 1 0.1647
AbsPreBCount IL-13 -8.6373 0.0290 1 0.1647
ProBH2AX G-CSF 3.1753 0.0293 1 0.1647
AbsMRCount IL-13 -2.1842 0.0299 1 0.1649
PBMonosCount M-CSF 0.1278 0.0312 1 0.1694
BcellH2AX RANTES 2.1314 0.0320 1 0.1708
BMMonosCount IL-6 0.0360 0.0346 1 0.1813
BMMonosCount RANTES 0.0356 0.0377 1 0.1946
PBNeutsCount IL-18 -1.3917 0.0415 1 0.2109
BMNeutsCount IL-1a 0.2216 0.0434 1 0.2172
Continued on next page
Table 2: Absolute plasma cytokine associations with immune cell phenotypes (continued)
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Outcome Module/Analyte Coef P-value FWER FDR
BMNeutsCount G-CSF 0.2204 0.0449 1 0.2193
PBNeutsCount IL-13 1.3635 0.0452 1 0.2193
ProBH2AX IL-13 2.9514 0.0477 1 0.2269
ImmatureBH2AX IL12p40 3.9099 0.0482 1 0.2269
Table 2: Absolute plasma cytokine associations with immune cell phenotypes (continued)
 27 
Table 2.3. Adjusted plasma cytokine associations with immune cell phenotypes 
 
 
Outcome Module/Analyte Coef P-value FWER FDR
AbsBCount G-CSF -19.5885 1.11E-07 3.57E-05 1.8762E-05
AbsPreBCount G-CSF -13.9993 1.17E-07 3.74E-05 1.8762E-05
AbsMRCount IL12p40 -3.4911 4.92E-07 1.57E-04 5.2507E-05
AbsMRCount G-CSF -3.4634 8.67E-07 2.75E-04 6.9397E-05
AbsBCount IL12p40 -18.6473 3.59E-06 0.0011 2.30E-04
AbsPreBCount IL12p40 -13.1377 7.96E-06 0.0025 4.25E-04
BMMonosCount IL12p40 0.0546 2.90E-05 0.0091 0.0012
PBMonosCount MCP-1 -0.2265 3.10E-05 0.0097 0.0012
PBNeutsCount G-CSF 1.9439 1.09E-04 0.0341 0.0039
PBNeutsCount IL-1a 2.4353 1.84E-04 0.0573 0.0059
BcellH2AX IL-1a 2.9229 4.87E-04 0.1510 0.0142
AbsMRCount IL-1a -2.8526 0.0012 0.3588 0.0310
BcellH2AX G-CSF 2.7655 0.0016 0.4870 0.0389
BMNeutsCount IL12p40 0.2955 0.0022 0.6754 0.0477
PBNeutsCount MIP-1B 1.3384 0.0022 0.6841 0.0477
AbsBCount IL-1a -15.0445 0.0026 0.7785 0.0510
PBNeutsCount IL12p40 1.8573 0.0033 1 0.0619
BMNeutsCount IL-1a 0.2862 0.0037 1 0.0619
AbsPreBCount IL-1a -10.5099 0.0037 1 0.0619
BMMonosCount M-CSF 0.0445 0.0042 1 0.0679
PBMonosCount IL12p40 0.1948 0.0051 1 0.0716
AbsPreBCount M-CSF -10.2560 0.0052 1 0.0716
AbsPreBCount MIP-1B -10.2373 0.0053 1 0.0716
AbsBCount MIP-1B -14.3072 0.0054 1 0.0716
AbsPreBCount IL-6 -10.1129 0.0062 1 0.0779
BcellH2AX MIP-1B 2.5268 0.0063 1 0.0779
BMMonosCount G-CSF 0.0430 0.0067 1 0.0792
AbsBCount M-CSF -13.9636 0.0073 1 0.0836
AbsBCount IL-6 -13.7374 0.0089 1 0.0978
BMMonosCount MCP-1 -0.0411 0.0113 1 0.1209
AbsMRCount MIP-1B -2.3959 0.0136 1 0.1403
Continued on next page
Table 3: Adjusted plasma cytokine associations with immune cell phenotypes
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Outcome Module/Analyte Coef P-value FWER FDR
BMNeutsCount IL-6 0.2509 0.0170 1 0.1703
AbsMRCount M-CSF -2.3229 0.0182 1 0.1761
BMMonosCount IL-1a 0.0383 0.0218 1 0.1960
PBNeutsCount IL-6 1.5024 0.0219 1 0.1960
BMMonosCount IL-12p70 -0.0382 0.0220 1 0.1960
AbsMRCount IL-6 -2.2376 0.0249 1 0.2100
PBNeutsCount IL-18 -1.4807 0.0249 1 0.2100
PBNeutsCount LIF -1.1018 0.0265 1 0.2177
BcellH2AX IL12p40 2.1665 0.0284 1 0.2260
AbsMRCount MCP-1 2.1936 0.0290 1 0.2260
BMMonosCount IL-5 -0.0366 0.0312 1 0.2380
BMMonosCount IL-9 -0.0353 0.0394 1 0.2889
BMNeutsCount G-CSF 0.2248 0.0397 1 0.2889
BMNeutsCount MIP-2 -0.2233 0.0414 1 0.2941
BMMonosCount Eotaxin 0.0350 0.0423 1 0.2941
PBMonosCount IL-2 -0.1402 0.0446 1 0.3037
PBMonosCount G-CSF 0.1488 0.0467 1 0.3112
Table 3: Adjusted plasma cytokine associations with immune cell phenotypes (continued)
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Table 2.4. Absolute plasma module associations with immune cell phenotypes 
 
 
Outcome Module/Analyte Coef P-value FWER FDR
PBMonosCount PM3 0.2428 7.2166E-05 0.0022 0.0022
PBNeutsCount PM3 2.0589 0.0018 0.0511 0.0264
BMMonosCount PM3 0.0430 0.0067 0.1864 0.0513
AbsPreBCount PM3 -10.0407 0.0068 0.1864 0.0513
AbsBCount PM3 -13.7786 0.0086 0.2228 0.0514
BcellH2AX PM3 2.4232 0.0103 0.2586 0.0517
AbsMRCount PM3 -2.4233 0.0121 0.2908 0.0519
ImmatureBH2AX PM3 4.5961 0.0140 0.3225 0.0526
ProBH2AX PM3 3.4070 0.0164 0.3603 0.0546
BMNeutsCount PM3 0.1876 0.1003 1 0.3010
ProBH2AX PM2 2.2825 0.1465 1 0.3997
ImmatureBH2AX PM2 2.8602 0.1739 1 0.4348
PBNeutsCount PM1 -0.8918 0.2592 1 0.5982
PBNeutsCount PM2 1.1437 0.2893 1 0.6198
ImmatureBH2AX PM1 2.0863 0.3358 1 0.6716
PBMonosCount PM2 0.1043 0.3774 1 0.7076
BcellH2AX PM2 0.9246 0.4085 1 0.7143
BMNeutsCount PM1 -0.0966 0.4286 1 0.7143
AbsMRCount PM1 0.6597 0.5660 1 0.7844
AbsMRCount PM2 -0.6352 0.5809 1 0.7844
ProBH2AX PM1 0.9049 0.5877 1 0.7844
BcellH2AX PM1 -0.5991 0.5974 1 0.7844
BMMonosCount PM1 0.0101 0.6013 1 0.7844
BMNeutsCount PM2 0.0571 0.6446 1 0.8057
AbsBCount PM1 2.6975 0.6717 1 0.8060
AbsPreBCount PM1 1.4573 0.7495 1 0.8433
PBMonosCount PM1 0.0258 0.7763 1 0.8433
AbsBCount PM2 -1.7260 0.7870 1 0.8433
AbsPreBCount PM2 -0.8457 0.8533 1 0.8828
BMMonosCount PM2 -0.0028 0.8870 1 0.8870
Table 4: Absolute plasma module associations with immune cell phenotypes
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Table 2.5. Adjusted plasma module associations with immune cell phenotypes 
 
  
   
Outcome Module/Analyte Coef P-value FWER FDR
AbsBCount PM5 -18.5633 4.62E-06 2.31E-04 9.53E-05
AbsPreBCount PM5 -13.2290 5.56E-06 2.72E-04 9.53E-05
PBNeutsCount PM5 2.0300 5.72E-06 2.75E-04 9.53E-05
AbsMRCount PM5 -3.2836 1.68E-05 7.91E-04 2.10E-04
BcellH2AX PM5 2.8579 8.17E-04 0.0376 0.00817
BMNeutsCount PM5 0.2890 0.0032 0.1419 0.02629
BMMonosCount PM5 0.0431 0.0065 0.2882 0.04678
Table 5: Adjusted plasma module associations with immune cell phenotypes
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CHAPTER 3: DECREASED LEVELS OF IL-10 ACCELERATE THE DEVELOPMENT OF B 
CELL DISEASE 
 
3.1 INTRODUCTION  
Given the association between IL-10 deficiency and increased risk of childhood B cell 
lymphoblastic leukemia11,62,63 and B cell lymphoma12 in humans, we sought to determine whether 
decreased levels of IL-10 contribute to the development of disease in a mouse model of B cell 
leukemia/lymphoma. The coordination between pre-existing genetic lesions and inflammatory 
cues can contribute to the development of pediatric B-ALL.   Two well-supported mechanisms of 
inflammation-driven B leukemogenesis are (1) selection of B cell clones harboring initiating 
mutations that confer a competitive advantage in inflammatory milieus and (2) aberrant activation 
of RAG and AID endonucleases, resulting in mutagenesis of Ig and non-Ig genes. These 
pathways have been observed in disease models that have relied on the induction of specific 
inflammatory conditions including aging-induced inflammation53 and TLR stimulation8,64.  
Interestingly, we have observed increased B cell suppression and DNA damage in Il10-/- mice 
with inflammation. Therefore, we propose that inflammation in Il10-/- mice, rather than a direct loss 
of IL-10 signaling, can contribute to the development of B cell malignancies in a disease model. 
Infections and inflammation are capable of driving the selection of B cell progenitors with 
pre-existing oncogenic lesions, which may lead to leukemia development.  Whereas normal B cell 
progenitors are suppressed by aging-associated inflammation,  B cells with oncogenic lesions 
such as BCR-ABL, NRASV12, and Myc, are resistant to the suppressive effects of the aged-
inflammatory environment53. The mutated population of B cells can undergo an expansion in 
compartment size over time, suggesting that they may eventually develop into B-ALL.   Whether 
similar inflammatory responses are capable of driving the selection of in pre-leukemic clones in 
young mice is unclear. In the Pax5+/- model of B-ALL, exposing young mice to infectious 
pathogens results in B cell suppression and permits the acquisition of somatic mutations in Jak352.  
Interestingly, several pro-inflammatory cytokines that drive aging inflammation are also elevated 
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during spontaneous inflammatory responses in young Il10-/- mice. It is therefore feasible that 
inflammation in young Il10-/- mice may favor the selection of B cells with oncogenic mutations and 
lead to subsequent leukemic development.   
Another mechanism of pathogenesis that is related to chronic inflammation is increased 
tissue damage caused by activated neutrophils.   Other groups have established that Il10-/- mice 
with colitis have extensive DNA damage in peripheral blood lymphocytes in comparison to Il10-/- 
mice without colitis or wild-type controls18.  No previous studies have reported whether the DNA 
damage in Il10-/-mice extends to the B cell compartment of the bone marrow.  Of note, the TLR4 
agonist LPS in combination with withdrawal of IL-7 from B cell culture conditions is able to induce 
DNA damage in B cells by increasing the activity of the RAG and AID enzymes8, which are 
involved in VDJ recombination and somatic hypermutation (SHM).  Thus, selection of pre-
leukemic B cell clones and RAG/AID-mediated mutagenesis could represent processes that 
contribute to B cell leukemogenesis. 
 
3.2 RESULTS 
3.2.i IL-10 deficiency disrupts B cell properties in pre-leukemic mice 
To investigate the interactions between inflammation and B cell properties in a mouse 
model of B cell leukemia/lymphoma, we crossed Il10-/- mice to Cdkn2a-/- mice to generate 
Il10-/- Cdkn2a-/- mice.  Cdkn2a codes for the p16Ink4a and p19Arf (p14ARF in humans) tumor 
suppressor proteins, which are key regulators of the cell cycle.  CDKN2A loss is found in 1/3 of 
ALL65 and when the homolog of this gene is deleted in mice, B-ALL is induced with a 
penetrance of 40%23.  We hypothesized that the loss of IL-10 in Cdkn2a-/- mice would have a 
similar effect on inducing B cell loss and DNA damage as Il10 loss in mice with wild-type 
Cdkn2a.  Although no aberrations in B cell proliferation have been reported in Cdkn2a-/- mice, it 
is possible that the combination of Il10 and Cdkn2a deletions may coordinate to increase B cell 
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proliferation to a level that exceeds what we have observed in Il10-/- mice.  We demonstrated 
that pre-B cells in Il10-/- Cdkn2a-/- mice are less abundant than they are in control Cdkn2a-/- mice 
(Figure 3.1A).  The absence of IL-10 also increased the percent of DNA damage and 
proliferation in B cells relative to Cdkn2a-/- mice (Figure 3.1B).  FVB/n and Il10-/- mice were not 
included in this experiment, therefore we were unable to evaluate whether Cdkn2a loss 
coordinated with Il10 loss to further impact B cells.  However, it is worth noting that the fold 
change between Il10-/- and control mouse B cell numbers, DNA damage, and proliferation was 
similar across different experiments.  Therefore, the loss of IL-10 has similar effects on B cells in 
Cdkn2a wild-type mice and in the Cdkn2a-/- mouse model of B cell leukemia/lymphoma. 
3.2.ii IL-6 and IL-17 are associated with B cell DNA damage in pre-leukemic Il10-/- mice  
To confirm the association between inflammation and altered B cell properties in the 
context of Cdkn2a deletion, we measured cytokine concentrations in the blood of Cdkn2a-/- and 
Il10-/- Cdkn2a-/- mice.  We used the approach described in Chapter 2 to determine whether 
associations were present between individual cytokines or cytokine modules and B cell 
outcomes.  Linear regression of single cytokines showed an inverse correlation between pre-B 
cell numbers and the levels of G-CSF, IL-6, and IL-17 (Tables 3.1 and 3.2).   In our previous 
analysis of cytokine associations in Il10-/- mice, G-CSF had a similar negative correlation with 
pre-B cell number.  This result suggests that the relationship between G-CSF and pre-B cells 
persists in the presence of pre-leukemic mutations.  IL-6 and IL-17 on the other hand, were only 
correlated with low pre-B cell numbers in Il10-/- mice on the Cdkn2a-/- background.  This result 
could demonstrate that either Cdkn2a loss alters the pattern of cytokine expression in Il10-/- 
mice or that Cdkn2a-/- pre-B cells are more responsive to changes in IL-6 and IL-17 than pre-B 
cells from Cdkn2a wild-type mice.  Alternatively, our initial study in Cdkn2a wild-type mice may 
have been underpowered to detect differences in IL-6 and IL-17 due to the modest number of 
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evaluated mice and variability.  Overall, G-CSF was consistently associated with low pre-B cell 
numbers in Il10-/- mice regardless of whether Cdkn2a was deleted. 
 We also tested whether the cytokines in plasma 5 module (PM5) from Chapter 2 
retained an association with B cell DNA damage in Il10-/- Cdkn2a-/- mice.  These cytokines 
included IL-1a, IL-6, IL-12p40, IL-13, G-CSF, and MIP-1b.  Of the cytokines in PM5, only IL-6 
was independently associated with B cell DNA damage by linear regression (Table 3.1).  We 
also observed an association between IL-17 levels and B cell DNA damage.  We expected that 
modular analysis of cytokines may reveal significant correlations between a group of cytokines 
and B cell DNA damage, but did not find any such associations that withstood multiple 
hypothesis testing (data not shown).  These results demonstrate that although IL-6 is related to 
B cell DNA damage across non-pre-leukemic and pre-leukemic Il10-/- datasets, IL-17 is only 
associated with DNA damage in B cells in pre-leukemic Il10-/- Ckdn2a-/- mice.   Our data identify 
IL-6 and IL-17 as potential mediators of B cell DNA damage in Il10-/- mice, which is consistent 
with the characterization of these cytokines as ALL risk factors in human newborns66. 
3.2.iii IL-10 deficiency does not alter B cell number, DNA damage, or proliferation in the absence 
of monocyte inflammation   
To gain insight into the mechanism of B cell deficiency and DNA damage in Il10-/- 
Ckdn2a-/- mice, we addressed the dependency of these B cell properties on inflammation.  8-12 
week old Il10-/- Ckdn2a-/- mice with variable levels of inflammation were chosen and their bone 
marrow B cells were compared to Cdkn2a-/- mice.  Each Il10-/- mouse had an elevated count of 
peripheral blood monocytes or neutrophils relative to the average count of these populations in 
the control Cdkn2a-/- group.  Cytokine levels were strongly associated with myeloid cell counts in 
the peripheral blood (Tables 3.1 and 3.2), therefore we used monocyte and neutrophil counts 
as markers of inflammation. Il10-/- Cdkn2a-/- mice with neutrophil or monocyte counts > 2 
standard deviations above the average were classified as having elevated neutrophils 
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(neutrophilia) or elevated monocytes (monocytosis). Decreased numbers of bone marrow B 
cells were only observed in Il10-/- mice with neutrophilia (Figure 3.2A) and monoyctosis (Figure 
3.2B), however there was no significant correlation between B cell count and the number of 
myeloid cells in the blood. We next sought to compare B cell development, DNA damage, and 
proliferation between Il10-/- mice with and without elevated myeloid cell counts. Because 5 out of 
6 Il10-/- Cdkn2a-/- mice had neutrophilia, we were unable to draw comparisons of B cell 
properties between mice with normal and elevated neutrophil levels.  For this reason, blood 
monocyte count was the primary measure of inflammation in this experiment.  As expected, 
Il10-/- Cdkn2a-/- mice with monocytosis had impaired B cell development starting at the pre-B cell 
stage (Figure 3.2C) and increased DNA damage (Figure 3.2D) and proliferation (Figure 3.2E) 
in mature Lin+ B cells relative to Cdkn2a-/- mice. Interestingly, Il10-/- Cdkn2a-/- mice with normal 
monocyte levels had no detectable abnormalities in these B cell properties in comparison to 
Cdkn2a-/- mice. These results established that IL-10 deficiency in the absence of substantial 
monocyte-related inflammation is not sufficient to alter B cell abundance, DNA damage, or 
proliferation.   
3.2.iv Loss of IL-10 production in non-hematopoietic cells drives inflammation  
To better understand how the absence of IL-10 production induces inflammation and B 
cell deficiency in Il10-/- mice, we used a mouse model of ETV6-RUNX1 ALL. ETV6-RUNX1 is the 
most common chromosomal translocation in pediatric ALL and encodes the TEL-AML1 (TA) 
oncogenic protein. TA can coordinate with infectious exposures to promote ALL development8,9.  
In the Cdkn2a-/- mouse model, expression of an EGFP-labeled TA transgene increases the risk 
of B-ALL from 26% to 50% and allows for detection of pre-leukemic cells by flow cytometry23. We 
first used TA Cdkn2a-/- mice to identify how pre-leukemic B cells respond to IL-10 deficiency in 
different cellular compartments. To this end, we generated chimeric mice by transplanting 
pre-leukemic TA Cdkn2a-/- bone marrow from Il10+/+ or Il10-/- donor mice into irradiated Il10+/+ or 
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Il10-/- recipient mice (Figure 3.3A).  The resulting four groups of mice (Il10+/+ ® Il10+/+, Il10-/- ® 
Il10+/+, Il10+/+ ® Il10-/-, Il10-/-® Il10-/-) were bled on a monthly basis to track the growth dynamics 
of myeloid cells and pre-leukemic TA expressing B cells over time.     
 Since IL-10 is produced by hematopoietic and non-hematopoietic cells13, it is possible for 
IL-10 deficiency in either of these cellular compartments to disrupt myeloid and B cell 
homeostasis.   If a loss of IL-10 production in hematopoietic cells drives myeloid expansion, then 
we would expect the transplantation of Il10-/- donor marrow to induce higher myeloid counts in 
recipient mice than the transplantation of Il10+/+ donor marrow.  If, on the other hand, a 
non-hematopoietic Il10 deficiency is sufficient to induce inflammation, then all Il10-/- recipients 
should have elevated myeloid counts, regardless of donor strain.  An additional possibility is that 
Il10 deficiency in both hematopoietic and non-hematopoietic cells contributes to inflammation.  In 
this case, we would expect Il10-/- recipients of Il10-/- donor cells to have the highest level of myeloid 
expansion in comparison to any of the other three transplantation conditions. 
 Differences in the white blood cell counts were apparent as early as 5 weeks 
post-transplantation.  Based on studies that have demonstrated the importance of 
lymphoid-derived IL-10 suppressing immune cell activation67–69, we expected a loss of IL-10 in 
hematopoietic donor cells to induce an inflammatory response in FVB/n recipients. Surprisingly, 
the loss of IL-10 in hematopoietic donor cells had the opposite effect, which was suppression of 
granulocytes in FVB/n recipients (Figure 3.3B).  Therefore, the loss of IL-10 production in 
hematopoietic cells was not sufficient to induce an inflammatory response in Il10+/+ recipients.  
Instead, both groups of Il10-/- recipients had an increased percent of granulocytes along with a 
decreased percent of TA(EGFP+) granulocytes in the peripheral blood compared to FVB/n 
recipients (Figure 3.3B).  Additionally, Il10-/- recipients had decreased lymphocyte percentages 
relative to FVB/n recipients (Figure 3.3C).  We hypothesized that pre-leukemic lymphocytes in 
Il10-/- recipients may be resistant to inflammation-mediated suppression, however these mice had 
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a decreased percent of TA(EGFP+) lymphocytes (Figure 3.3C).  These data show that a B-cell 
extrinsic loss of IL-10 in the non-hematopoietic compartment drives myeloid expansion, and 
possibly inflammation, in Il10-/- mice. 
 
3.2.v Decreased levels of IL-10 accelerate B cell neoplasms in TEL-AML1 Cdkn2a-/- mice 
Children born with low levels of IL-10 were found to have a 25-fold increased risk of 
developing ALL11. Whether this association reflects causality had not been previously tested.  To 
determine whether low levels of IL-10 promote the development of B-cell leukemia/lymphoma, we 
followed a cohort of TA Cdkn2a-/- mice with wild-type IL-10 (Il10+/+ TA Cdkn2a-/-) for the 
development of disease alongside a cohort of mice with either decreased IL-10 expression (Il10+/- 
TA Cdkn2a-/-) or absent IL-10 expression (Il10-/- TA Cdkn2a-/-).  We did not observe a significant 
difference in the incidence of either solid tumors or leukemia/lymphomas among our survival 
cohorts (Table 3.3). Time to illness analysis revealed that a complete loss of IL-10 in the TA 
Cdkn2a-/- model significantly decreased cancer free survival (Figure 3.4A) and 
leukemia/lymphoma free survival (Figure 3.4B) relative to Il10+/+ controls.  The median time to 
leukemia/lymphoma in Il10-/- TA Cdkn2a-/- mice was 140 vs. 220 days for Il10+/+ TA Cdkn2a-/- mice 
(Table 3.4).  For Il10+/- TA Cdkn2a-/- mice, the median time to leukemia/lymphoma was 
intermediate at 174 days, supporting a dose-dependent relationship between decreased levels of 
IL-10 and early onset of leukemia/lymphoma.  Moreover, the latency of leukemia/lymphoma in 
ll10+/- TA Cdkn2a-/- mice was significantly shorter than that of the control Il10+/+ TA Cdkn2a-/- 
survival cohort (Mann-Whitney U-test p=0.0107).  These data demonstrate that low levels of IL-10 
increase the aggressiveness of leukemia/lymphoma development in the TA Cdkn2a-/- model by 
accelerating time to illness.  
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3.2.vi IL-10 loss increases frequency of C>G and C>T mutations in B cell neoplasms 
We next sought to determine whether the increased levels of B cell lesions observed in 
pre-leukemic Il10-/- mice corresponded to an increased mutational burden or altered mutational 
pattern in Il10-/- B-cell leukemia/lymphomas.  To this end, we used whole exome sequencing to 
characterize the number and type of mutations in B-cell leukemia/lymphomas from 9 Il10+/+ TA 
Cdkn2a-/- mice and 8 Il10-/- TA Cdkn2a-/- mice.  Total and nonsynonymous single nucleotide 
variants (SNVs) were similar in number between Il10+/+ and Il10-/- B cell leukemia/lymphomas 
(Figure 3.4C).  The total number of C>G and C>T mutations was increased in Il10-/- samples 
(Figure 3.4D), although we did not find evidence for enrichment of inflammation-related COSMIC 
mutational signatures.  Notably, C>T mutations are elevated in mouse tumors with IL-10 
deletions70. SNVs related to human cancer were found in a number of genes (Table 3.5), with 
synonymous Hoxa9 mutations in 63% of Il10-/- B cell leukemia/lymphomas (5 of 8).  Similar 
synonymous mutations in HOX9A been found in several lymphoid neoplasm cell lines with a high 
pathogenicity score71.  Although in the past, synonymous changes have been considered 
nonpathogenic, recent data suggests that these mutations have the potential to cause pathogenic 
effects72.  We also observed mutations in Jak3, Cdkn1a, and Dnm2, which have human orthologs 
that are mutated in human leukemias73–76.  The Jak3V670A mutation was present in 3 of 17 B cell 
leukemia/lymphomas and is a homolog of human JAK3V674A.  Other canonical cancer SNVs were 
identified in our cohort, however there was little overlap in SNVs among samples.  These results 
are consistent with sequencing data from human and mouse B-ALLs which provide evidence for 
a highly heterogeneous mutational landscape7,9,58,77.  Overall, our results demonstrate that 
although IL-10 is dispensable for B cell lymphopoiesis, the myeloid inflammation that results from 
impaired IL-10 production in non-hematopoietic cells may lead to B cell loss and early DNA 
damage. Furthermore, decreased levels of IL-10 cause acceleration of lymphoid malignancies 
with increased C>G and C>T mutations in the TA Ckdn2a-/- model of B cell leukemia/lymphoma. 
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3.3 DISCUSSION 
 
Our previous study, in which Cdkn2a-/- mice were genetically engineered to express TA in 
hematopoietic cells, revealed that following irradiation, TA positive B cells outcompeted TA 
negative cells23.  We also found that irradiation also led to an early onset of B-ALL23.  Thus, our 
initial expectation was that TA positive B cell numbers should increase in response to genotoxic 
stress associated with systemic inflammation in Il10-/- mice.  The fact that transplanted TA positive 
B cells did not have a selective growth advantage in the blood of Il10-/- recipient mice is not 
consistent with this prediction.  These observations raise the possibility that inflammation in Il10-
/- mice may not be a sufficient source of genotoxic stress to favor the early selection of TA 
expressing cells.  Analysis of cytokines and TA positive B cells in the bone marrow niche would 
be an interesting future direction that would address whether local changes in inflammatory 
environment select for pre-leukemic B cells.  
Our survival data demonstrate that decreased levels of IL-10 contributed to the development 
of B cell leukemia/lymphomas (including both immature and mature neoplasms, Figure 3.5).  This 
observation supports epidemiology studies that show an association between decreased IL-10 
expression or signaling and the development of pediatric B-ALL11 and DLBCL12.  Rather than 
solely being a risk factor for childhood ALL, IL-10 deficiency was shown here to have an impact 
on leukemia/lymphoma development in a model of ALL.  Our data supports that IL-10 deficiency 
indirectly disrupts B cell development, DNA damage, and proliferation through a monocyte-related 
inflammatory response.  Whether monocytic inflammation is necessary to accelerate 
leukemia/lymphoma in Il10-/- mice is a question that requires further investigation.  A future 
direction of particular interest is to delineate the impact of different inflammatory cell subsets on 
B cell DNA damage and disease in Il10-/- mice and neonates born with a predisposition for 
aberrant inflammatory responses.  Given that SNPs that are associated with low IL-10 production 
are predictive of low overall survival and relapse62,63, IL-10 therapy may be a suitable option for a 
subset of patients with aggressive disease.  A PEGylated form of IL-10 (PEG-IL10) is currently in 
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phase 2 clinical trials for adult solid tumors and it may be beneficial to consider the possibility that 
high-risk pediatric B-ALL could be a new indication for this drug.    
We had previously noted that our TA model developed both immature and mature B cell 
diseases in the presence of IL-10, but the most prevalent disease was B-ALL.  Based on human 
data linking IL-10 deficiency to elevated ALL risk, we expected IL-10 loss in the TA 
Cdkn2a-/- model to increase the incidence of B-ALL.  However, in the current study, the majority 
of Il10-/- TA Cdkn2a-/- mice developed myeloid hyperplasia due to inflammatory changes, including 
inflammatory bowel disease.  The onset of these inflammatory changes occurred between 1-2 
months of age, a timeframe that precedes leukemia/lymphoma development in the TA Cdkn2a-/- 
model.  Similar numbers of mice were generated for each survival cohort therefore, the number 
of mice ultimately at risk for B cell disease was lower in Il10-/- TA Cdkn2a-/- mice than in controls.  
That being said, both immature and mature B cell disease were observed in all survival cohorts.  
It should be noted that a small subset of cases could not be diagnosed after histopathological 
review.  Although the number of cases was too limited to reach as definitive conclusion, we 
observed a trend toward an increased proportion of mature B cell lymphomas and a decreased 
proportion of immature B cell leukemias in Il10-/- TA Cdkn2a-/- mice (Figure 3.5).  The opposite 
was true for Il10+/+ TA Cdkn2a-/- mice.  Both pro-B cells and IgM+ immature B cells displayed 
increased DNA damage in in pre-leukemic Il10-/- Cdkn2a-/- mice relative to Cdkn2a-/- controls, 
suggesting the potential for immature or mature B cell disease to develop.  However, the increase 
in DNA damage was greater in the IgM+ B cell population, which also had a proliferative 
advantage in Il10-/- Cdkn2a-/- mice.  These factors could explain why IgM+ and Ig Kappa+ B cell 
lymphomas were more common in Il10-/- TA Cdkn2a-/- mice. 
Differences between the pattern of IL-10 deficiency in the human and mouse studies could 
also explain a shift in the incidence of immature and mature B cell disease.  In our mouse study, 
decreased IL-10 expression was achieved through a constitutive knockout of one or both alleles 
of the Il10 gene.  This resulted in decreased IL-10 expression throughout the lifetime of the mice, 
 41 
as opposed to the decreased IL-10 expression that was detected at birth in the human cohort.  
We do not know whether low IL-10 levels were sustained in humans after birth; however genetic 
analysis of the IL-10 locus did not reveal any mutations that were associated with a prolonged 
decrease in IL-10 production (unpublished observation, Adam de Smith).  In order to model a 
temporal decrease of IL-10 at birth, mice could be treated with an IL-10 blocking antibody or 
engineered to have a conditional knockout of Il10.    
Another difference between the human and mouse studies was the number of genetic 
subtypes that were included in analysis.  Multiple genetic subtypes of ALL developed in children 
born with low levels of IL-10, however only TA expressing mice were examined in the current 
study.  Based on the data in Chang, et al., we did not expect decreased levels of IL-10 to 
coordinate with any particular initiating genetic lesion.  However, there was a limited number of 
human ALLs with subtype data, which could have reduced the statistical power to detect an effect 
of a particular genetic lesion on ALL risk in the context of low IL-10 levels.  A useful future direction 
would be to test whether low birth levels of IL-10 have the same impact on ALL risk for children 
born with different initiating genetic lesions. 
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3.4 FIGURES 
 
Figure 3.1. Bone marrow B cells in pre-leukemic Il10-/- Cdkn2a-/- mice are reduced and 
have elevated levels of DNA damage. 
Analysis of 8-12 week-old Cdkn2a-/- and Il10-/- Cdkn2a-/- mice.  Absolute bone marrow count of 
(A) Total B220+ CD19+ B cells and Bone marrow B cell subsets.    Percent of H2AX+ cells 
among (B) Total bone marrow B cells and Bone marrow B cell subsets.  Bar graph data show 
mean ± SD.  Mann-Whitney U-test.  *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.001.   
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Figure 3.2. IL-10 is disposable for B cell homeostasis in the absence of elevated 
peripheral blood monocytes. 
(A) Correlation between number of B cells in the bone marrow and peripheral blood count of 
neutrophils or (B) monocytes.  Pearson correlation test excluding Il10 wild-type Cdkn2a-/- mice.  
(C) Number, (D) percent gH2AX, and (E) percent BrdU of pro-B cells (B220+ CD19+ CD43+), pre-
B cells (B220+ CD19+ CD43-), Lin+ B cells (B220+ CD19+ Lin+) in the bone marrow. Lineage 
cocktail (IgM, TER119, NK1.1, CD3e, TCRab, TCRld, Gr1, Ly6C) Bar graph data show mean ± 
SD.  Mann-Whitney U-test.  *p ≤ 0.05, **p ≤ 0.01. 
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Figure 3.3. IL-10 loss in non-hematopoietic cells is necessary for induction of 
inflammatory response. 
(A) Schematic diagram of bone marrow transplantation and tracking of peripheral blood cells in 
sublethally irradiated recipient mice (n=5 Il10+/+ ® Il10+/+, n=4 Il10-/- ® Il10+/+, n=5 Il10+/+ ® Il10-/-
, n=5 Il10-/- ® Il10-/-).  (B) Frequency of total and TA+(EGFP+) granulocytes and (C) 
lymphocytes at 5- and 9-weeks post-transplantation. Symbols and error bars show mean ± SD.  
Mann-Whitney U-test.  *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.001.   
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Figure 3.4. Decreased levels of IL-10 accelerate development of B-cell disease in TA 
Cdkn2a-/- model. 
 
(A) Survival curves of cancer and (B) leukemia/lymphoma development in Il10+/+ TA Cdkn2a-/- 
mice and Il10-/- TA Cdkn2a-/- mice. (C) Number of total or nonsynonymous single nucleotide 
variants (SNVs) in B cell leukemia/lymphomas from exome sequencing of 9 Il10+/+ TA Cdkn2a-/- 
mice and 8 Il10-/- TA Cdkn2a-/- mice. (D) Mutation spectrum representing context of 96 possible 
trinucleotide contexts in sequenced Il10+/+ TA Cdkn2a-/- and Il10-/- TA Cdkn2a-/- B cell 
leukemia/lymphomas. Gehan-Breslow-Wilcoxon test was applied to survival curves. 
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Figure 3.5. Lineage characterization of leukemia/lymphomas in survival cohorts of TA 
Cdkn2a-/- mice with wild-type, heterozygous, or null Il10. 
Pie charts displaying the percent of leukemia/lymphomas characterized as Immature B cell 
leukemias, Mature B cell lymphomas, non-B cell leukemia/lymphoma, and undermined lineage.  
Table displays total number and percent of leukemia/lymphoma lineages belonging to each 
genotype. 
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3.5 TABLES 
 
Table 3.1. Absolute plasma cytokine associations with immune phenotypes 
(pre-leukemic dataset) 
 
 
 
Outcome Module/Analyte Coef P-value FWER FDR
AbsPreBCount IL-17A -0.671343 4.82E-08 9.25E-06 7.88E-06
PBNeutsCount IL-10 1.802837 8.21E-08 1.57E-05 7.88E-06
AbsBCount MIP-1a -1.281207 1.83E-07 3.48E-05 1.17E-05
AbsBCount IL-6 -1.259533 5.67E-07 0.000107 2.41E-05
AbsBCount IL-17A -1.25749 6.27E-07 0.000118 2.41E-05
PBMonosCount IL-10 0.147138 8.53E-07 0.000159 2.73E-05
AbsBCount G-CSF -1.224673 2.75E-06 0.000511 7.53E-05
BcellH2AX IL-17A 0.060934 1.15E-05 0.002133 0.000257
AbsPreBCount IL-6 -0.609466 1.3E-05 0.002385 0.000257
PBNeutsCount MIP-1a 1.028502 1.34E-05 0.002448 0.000257
PBMonosCount MIP-1a 0.086086 1.55E-05 0.002814 0.00027
AbsPreBCount MIP-1a -0.590058 4.34E-05 0.007852 0.000694
AbsPreBCount G-CSF -0.579227 7.9E-05 0.014214 0.001136
BcellH2AX IL-6 0.057657 8.28E-05 0.014825 0.001136
PBMonosCount RANTES 0.097701 9.71E-05 0.017287 0.001243
AbsMRCount MIP-1a -0.376393 0.000435 0.076952 0.005217
PBNeutsCount IL-6 0.979095 0.000465 0.081815 0.00525
AbsBCount IL-9 -1.03955 0.000589 0.103099 0.006284
PBNeutsCount IL-17A 0.991938 0.000818 0.142266 0.008262
AbsMRCount MCP-1 -0.362075 0.000965 0.166918 0.009263
BcellH2AX G-CSF 0.05166 0.001111 0.191084 0.009835
PBNeutsCount RANTES 1.062669 0.001127 0.192696 0.009835
AbsMRCount G-CSF -0.35737 0.001227 0.208593 0.010243
AbsBCount MCP-1 -0.99844 0.001283 0.216799 0.010263
PBMonosCount IL-6 0.078258 0.0014 0.235171 0.01064
PBNeutsCount KC 0.882394 0.001441 0.240624 0.01064
AbsMRCount IL-6 -0.353136 0.001511 0.250783 0.010743
AbsPreBCount IL-9 -0.507366 0.001607 0.265225 0.010812
AbsBCount IL12p40 -0.984529 0.001633 0.26783 0.010812
AbsBCount TNF-a -0.981647 0.001715 0.279492 0.010974
Table 3.1: Absolute plasma cytokine associations with immune pheonotypes (pre-
leukemic dataset)
Continued on next page
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Outcome Module/Analyte Coef P-value FWER FDR
PBNeutsCount IL-1a 1.545251 0.002447 0.396453 0.015157
AbsBCount IL-12p70 -0.956596 0.002575 0.414505 0.015447
AbsBCount IFN-gamma -0.945676 0.003046 0.487297 0.01772
AbsBCount RANTES -0.940866 0.003274 0.520582 0.018489
AbsBCount IL1b -0.919147 0.004485 0.708586 0.02397
PBNeutsCount Eotaxin 0.858479 0.004494 0.708586 0.02397
PBMonosCount G-CSF 0.069702 0.004855 0.757417 0.025195
PBMonosCount IL-17A 0.07508 0.005108 0.791767 0.025286
AbsMRCount IFN-gamma -0.324673 0.005136 0.791767 0.025286
PBMonosCount MIP-1B 0.079624 0.005453 0.834247 0.025648
PBMonosCount KC 0.068183 0.005571 0.84678 0.025648
PBNeutsCount G-CSF 0.821619 0.00561 0.847176 0.025648
AbsPreBCount RANTES -0.461297 0.006147 0.922055 0.027447
PBMonosCount MIG 0.066348 0.00659 0.98188 0.028262
AbsPreBCount IL12p40 -0.458007 0.006682 0.989004 0.028262
AbsPreBCount TNF-a -0.457483 0.006771 0.995345 0.028262
BcellH2AX IL-1a 0.045507 0.006947 1 0.02838
AbsMRCount IL12p40 -0.315852 0.007121 1 0.028483
PBNeutsCount MIP-1B 0.923548 0.007692 1 0.030138
AbsPreBCount IL-1a -0.438829 0.010582 1 0.040633
BcellH2AX IL-9 0.043202 0.011973 1 0.045076
AbsMRCount IL-9 -0.295558 0.013991 1 0.051374
AbsMRCount IL-12p70 -0.29512 0.014181 1 0.051374
AbsPreBCount IL1b -0.42468 0.014453 1 0.05139
PBMonosCount IL-18 0.069569 0.016001 1 0.05503
AbsBCount IL-1a -0.815176 0.016051 1 0.05503
AbsPreBCount MCP-1 -0.417554 0.016777 1 0.056511
AbsMRCount IL-17A -0.287729 0.017707 1 0.058616
AbsPreBCount IFN-gamma -0.411488 0.018971 1 0.061736
PBMonosCount IL-1a 0.108553 0.021268 1 0.068056
Table 3.1: Absolute plasma cytokine associations with immune pheonotypes (pre-
leukemic dataset)
Continued on next page
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Outcome Module/Analyte Coef P-value FWER FDR
PBNeutsCount MCP-1 0.680833 0.022925 1 0.072157
AbsMRCount MIP-1B -0.277399 0.023713 1 0.073433
AbsMRCount TNF-a -0.276484 0.02431 1 0.074088
PBNeutsCount MIG 0.685101 0.027471 1 0.082413
PBMonosCount IL12p40 0.060765 0.028785 1 0.085027
AbsMRCount IL1b -0.267095 0.031121 1 0.090534
PBNeutsCount IL-12p70 0.808751 0.032375 1 0.092775
AbsPreBCount IL-12p70 -0.378063 0.035211 1 0.098005
AbsBCount MIP-1B -0.734283 0.035221 1 0.098005
PBMonosCount MCP-1 0.053758 0.036447 1 0.099969
PBNeutsCount IL-18 0.738662 0.039875 1 0.10783
PBNeutsCount GM-CSF 0.624582 0.041866 1 0.111642
PBNeutsCount IFN-gamma 0.639359 0.043425 1 0.114214
AbsPreBCount IL-3 -0.36259 0.045492 1 0.118033
PBNeutsCount IL1b 0.639253 0.046253 1 0.118407
Table 3.1: Absolute plasma cytokine associations with immune pheonotypes (pre-
leukemic dataset)
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Table 3.2. Adjusted plasma cytokine associations with immune phenotypes 
(pre-leukemic dataset) 
 
 
Outcome Module/Analyte Coef P-value FWER FDR
BcellH2AX IL-17A 0.047908 0.003658 0.702388 0.332997
AbsPreBCount IL-17A -0.47513 0.004256 0.812966 0.332997
AbsMRCount Basic FGF 0.323874 0.005295 1 0.332997
BcellH2AX IL-6 0.045513 0.006937 1 0.332997
AbsBCount MIP-1a -0.793214 0.020174 1 0.616739
AbsMRCount LIF 0.281834 0.02097 1 0.616739
BcellH2AX IL-4 -0.040005 0.023154 1 0.616739
AbsBCount IL-6 -0.752354 0.029931 1 0.616739
PBMonosCountIL-10 0.098114 0.031705 1 0.616739
AbsPreBCount IL-6 -0.381448 0.033213 1 0.616739
AbsBCount IL-17A -0.733918 0.035334 1 0.616739
PBMonosCountIL-13 -0.056372 0.039132 1 0.617357
AbsBCount Basic FGF 0.711039 0.043003 1 0.617357
PBNeutsCount IL-10 1.105219 0.046111 1 0.617357
Table 3.2: Adjusted plasma cytokine associations with immune pheonotypes 
(pre-leukemic dataset)
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Table 3.3. Disease outcomes in Il10+/+, Il10+/-, and Il10-/- mice on the TA Ckdn2a-/- 
background 
 
 
TA Cdkn2a -/- 
(n=40)
Il10 +/- TA Cdkn2a -/- 
(n=31)
Il10 -/- TA Cdkn2a -/- 
(n=37)
30 (75%) 21 (68%) 17 (46%)
Leukemia/Lymphoma 21 (53%) 9 (29%) 12 (32%)
Solid tumor 11 (28%) 13 (42%) 6 (16%)
10 (25%) 10 (32%) 20 (54%)
Unknown 6 (15%) 4 (13%) 1 (3%)
Myeloid hyperplasia 
or Inflammation 0 (0%) 2 (6%) 18 (49%)
4 (10%) 4 (13%) 1 (3%)
N (% total)
Table 3.3: Disease outcomes in  Il10 +/+, Il10 +/-, and Il10 -/- mice on the TA Cdkn2a -/- 
background
Not Cancer
Tissue Unavailable 
Cancer
 52 
Table 3.4. Median cancer latency of Il10+/+, Il10+/-, and Il10-/- mice on the TA Ckdn2a-/- 
background 
 
Il10 +/+ TA Cdkn2a -/- 
(n=40)
Il10 +/- TA Cdkn2a -/- 
(n=31)
Il10 -/- TA Cdkn2a -/- 
(n=37)
Cancer 229 203 182
     Leukemia/Lymphoma 253 Undefined 232
     Solid tumor 281 275 234
Table 3.4 Median cancer latency of Il10 +/+, Il10 +/-, and Il10 -/- mice on the TA Cdkn2a -/- 
background
Median latency (days)
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Table 3.5. List of COSMIC database genes with SNVs from whole-exome sequencing of B 
cell leukemia/lymphomas from Il10+/+ TA Ckdkn2a-/- and Il10-/- TA Ckdkn2a-/- 
 
Gene Total SNV count
Il10 +/+ TA 
Ckdn2a -/-
Il10 -/- TA 
Ckdn2a -/-
Hoxa9 7 2 5
Jak3 3 2 1
Cdkn1a 3 3 0
Dnm2 3 3 0
Trrap 2 1 1
Alk 2 2 0
Ptpn11 2 2 0
Cblb 1 0 1
Cdh10 1 0 1
Ciita 1 0 1
Ddx10 1 0 1
Erc1 1 0 1
Isx 1 0 1
Jak2 1 0 1
Kmt2d 1 0 1
Maml2 1 0 1
Mllt3 1 0 1
Myh11 1 0 1
Ncor2 1 0 1
Pbx1 1 0 1
Polg 1 0 1
Sep9 1 0 1
Setd2 1 0 1
Six2 1 0 1
Xpo1 1 0 1
Aff4 1 1 0
Aspscr1 1 1 0
Atr 1 1 0
Bcl11b 1 1 0
Btk 1 1 0
Cbl 1 1 0
Chic2 1 1 0
Cic 1 1 0
Csmd3 1 1 0
Ctnna2 1 1 0
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Gene Total SNV count
Il10 +/+ TA 
Ckdn2a -/-
Il10 -/- TA 
Ckdn2a -/-
Ddr2 1 1 0
Ddx3x 1 1 0
Epha7 1 1 0
Erbb2 1 1 0
Flna 1 1 0
Flt4 1 1 0
Ikbkb 1 1 0
Il7r 1 1 0
Kit 1 1 0
Lats2 1 1 0
Met 1 1 0
Mn1 1 1 0
Msh6 1 1 0
Nf1 1 1 0
Pax3 1 1 0
Pax5 1 1 0
Pax7 1 1 0
Phf6 1 1 0
Pten 1 1 0
Rap1gds1 1 1 0
Runx1t1 1 1 0
Stat5b 1 1 0
Tbx3 1 1 0
Ubr5 1 1 0
Ywhae 1 1 0
Zfhx3 1 1 0
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CHAPTER 4: ALTERING THE INFLAMMATORY MILIEU INFLUENCES B CELL DNA 
DAMAGE AND THE DEVELOPMENT OF B CELL NEOPLASMS  
 
4.1 INTRODUCTION 
Pro-inflammatory cytokines are major regulators of blood cell function that can contribute 
to the development of hematopoietic malignancies78. ALL risk is associated with IL-10 
deficiency11 and high levels of IL-6, IL-17, and IL-18 at birth66. After the development of disease, 
elevated levels of TNFα, IL-1b, IL-12, and GM-CSF distinguish the cytokine profile of bone 
marrow supernatant of pediatric ALL patients from healthy donors1. The inflammatory state in 
neonates predisposed to ALL and children with ALL has similar features as innate immune 
responses mediated through myeloid cell activation. Although myeloid cells are conventionally 
the main population that is activated and mobilized in innate immune response, genetic lesions 
can allow provide B cells with the capacity to respond favorably to pro-inflammatory cytokines. 
Under particular inflammatory conditions, TEL-AML1 expression in B cell progenitors can induce 
co-expression of myeloid cell genes79, confer a competitive advantage over normal cells22,23,79, 
and increase reactive species-induced DNA damage80. Pro-inflammatory cytokines therefore 
have the potential to regulate the transformation of specific B cell clones during the 
development of disease. The mechanism by which pro-inflammatory cytokine production 
becomes dysregulated and contributes to childhood leukemia is largely unknown.  
In Il10-/- mice, the increased presence of H. pylori contributes to myeloid cell expansion 
and dysregulation of splenic B cell differentiation24. Microbial species can also play a role in B 
cell mutagenesis and have been proposed to impact ALL risk. Within the lamina propria, VDJ 
recombination and receptor editing of pro-B and pre-B cells are stimulated by microbial signals 
in the gut81. The impact of gut microbes on B cell progenitors that reside in more distal sites of 
lymphoid development, such as the bone marrow, is less well understood. Others have 
demonstrated that microbial signals can indirectly induce hematopoietic progenitor expansion by 
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stimulating myeloid cell production of IL-1b, IL-6, and TNF-a82. We were particularly interested 
in addressing whether microbial signals in Il10-/- mice may increase the level of DNA damage in 
B cell progenitors in the bone marrow.  Based on our observation that DNA damage in bone 
marrow B cells was associated with an IBD related cytokine signature in Il10-/- mice, we 
hypothesized that increased B cell DNA damage in Il10-/- mice was mediated through the gut 
microbiome. We aimed to address this question by using antibiotics to alter the gut microbiome 
of Il10-/- mice. Longitudinal analysis of the infection history within our SPF animal facility 
provided additional insight into how parasite-microbe interactions may influence the 
development of disease in mouse models of childhood leukemia. 
 
4.2 RESULTS 
4.2.i Antibiotic-mediated suppression of the inflammatory milieu promotes recovery of B cell 
development and diminishes B cell DNA damage 
Others have found that the colonization of the gut with specific bacterial species is required 
for myeloid and B cell expansion in Il10-/- mice.  Notably, treatment of Il10-/- mice with antibiotics 
that target helicobacter species limits the expansion of myeloid and marginal zone B cells24.  
Given the strong association between the cytokines that are elevated in Il10-/- mice on the FVB/n 
background and IBD, we reasoned that microbial dysbiosis may be an underlying cause of 
inflammation, bone marrow B cell deficiency, and elevated B cell DNA damage.  
Given the probability that the microbial milieu was contributing to B cell DNA damage in 
Il10-/- mice, we investigated the effect of antibiotics on inflammation and B cell properties in pre-
leukemic mice. To this end, we administered a 4-week regimen of antibiotics that target 
Helicobacter species or a placebo treatment to Cdkn2a-/- or Il10-/- Cdkn2a-/- mice (Figure 4.1A).  
Cytokine concentration in the peripheral blood was monitored before and after treatment by using 
a multiplex Luminex assay. Strikingly, antibiotic treatment reduced the concentration of several 
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cytokines that were associated with B cell deficiency and B cell DNA damage in Il10-/- Cdkn2a-/- 
mice including G-CSF, IL-6, and IL-17 (Figure 4.1B). This effect was also observed in antibiotic-
treated Cdkn2a-/- mice with wild-type IL-10, which had statistically significant decreases in G-CSF 
and IL-6 relative to placebo-treated controls. We next assessed the impact of antibiotics on the 
frequency of immune cells and the extent of DNA damage in B cells residing in the bone marrow.  
As expected, IL-10 loss in placebo-treated mice resulted in an increased frequency of peripheral 
blood CD11b+ myeloid cells (data not shown).  The expansion of myeloid cells within the bone 
marrow compartment of Il10-/- Cdkn2a-/- mice was attenuated by antibiotics (Figure 4.1C).  
Antibiotic treatment also partially abrogated the decrease in B cell number (Figure 4.1D) and 
remarkably reversed the increased B cell DNA damage (Figure 4.1E) that was observed in 
placebo-treated Il10-/- Cdkn2a-/- mice.  These results are consistent with the hypothesis that 
microbial dysbiosis disrupts B cell development and contributes to B cell DNA damage in pre-
leukemic Il10-/- mice. 
 
4.2.ii Pinworm outbreak supports a role of Th2 immunity in B-ALL 
Given that, in the context of decreased IL-10 levels, antibiotics achieved a partial 
restoration of B cell numbers and reduced B cell DNA damage, it follows that modifications to the 
commensal gut microbiome that suppress aberrant inflammation may protect against leukemia. 
Although infectious exposures are sufficient for B-ALL induction in Sca-1 ETV6-RUNX1 mice9, it 
has yet to be determined whether resolving infections in ETV6-RUNX1 positive mice can protect 
against B-ALL.  Over the course of several years, we noted a shift in the latency of 
leukemia/lymphoma in TA Cdkn2a-/- mice as compared with Cdkn2a-/- mice that lacked TA.  
Although these mice were continuously housed within the same room of our SPF facility, we were 
aware that pathogens were identified from time to time in our facility, and we hypothesized such 
a variation in milieu might explain our observation of a change in disease latency.  Our approach 
to address this hypothesis was to compare our survival analyses of leukemia/lymphoma incidence 
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and latency in TA Cdkn2a-/- and Cdkn2a-/- mice housed in our SPF facility from 2009-2017, along 
with review of sentinel mouse infection records. 
In separate experiments conducted in the 2009-2017 timeframe, we followed the survival 
of TA Cdkn2a-/- and Cdkn2a-/- mice in our SPF facility (Figure 4.2A). From 2009-2011, we noted 
differences in disease development between these two strains. Specifically, TA Cdkn2a-/- mice 
had an increased incidence and decreased latency of leukemia/lymphoma in comparison to 
Cdkn2a-/- mice (Figure 4.2B).   Our interpretation of this result was that TA coordinated with 
Cdkn2a deletion to generate lymphoid leukemia/lymphoma.  To our surprise, from 2015-2017, TA 
appeared to no longer impact the latency of B-ALL in the Cdkn2a-/- model, as demonstrated by 
two independent experiments showing overlap (Figure 4.2C) or minimal separation (Figure 4.2D) 
between the TA Cdkn2a-/- and Cdkn2a-/- survival curves.  Work from other investigators suggested 
that in some settings TA requires the presence of infectious exposures to initiate ALL in mice9.  
We therefore suspected that the effect of TA on driving leukemia/lymphoma during 2009-2011 
might be explained by a pathogen in our SPF facility that was eliminated by 2015, when the effect 
of TA was no longer observed.  Review of sentinel health records spanning 2009-2017 revealed 
that in 2013 the pinworm Aspiculuris was detected by fecal float, leading to the treatment of all 
cages in the room with Fenbendazole (Figure 4.2A).  Given the low sensitivity of the fecal float 
test relative to PCR, it is possible that pinworm infection was widespread within the room and 
present in non-sentinel cages from 2009-2011. These data suggest that pinworm infection was 
an important factor in the effect of TA on the acceleration of leukemia/lymphoma development in 
Cdkn2a-/- mice.  
To determine whether intentional pinworm infection could restore the leukemogenic effect 
of TA in the Cdkn2a-/- model, we exposed mice to pinworm shortly after weaning (Figure 4.2A). 
This was accomplished by transferring 4-week-old Cdkn2a-/- and TA Cdkn2a-/- mice from our 
fenbendazole-treated SPF facility to a conventional facility where they were housed with bedding 
from pinworm-infected mice.  This experiment confirmed that, in the context of pinworm infection, 
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TA Cdkn2a-/- mice develop leukemia/lymphoma earlier and with a higher incidence than 
Cdkn2a-/- mice (Figure 4.2E).  Our observations were consistent with the hypothesis that 
treatment of infections can protect against leukemia/lymphoma by limiting the coordination 
between TA and infectious stimuli. 
Further, we assessed whether the effect of pinworm could be attributed to enhanced 
leukemia development in TA Cdkn2a-/- mice or suppressed leukemia development in Cdkn2a-/- 
mice. Mice infected with pinworm have increased activation of B cells and Tregs that mediate 
Th2-directed suppression of Th1 and Th17 immune responses83. It is therefore feasible for 
pinworm infection to drive lymphoma development through B cell stimulation or to protect against 
cancer by suppressing chronic inflammation.  A limited number of studies have demonstrated that 
CpG, a TLR9 agonist, can suppress the development of B-ALL in mice64,84,85. However, no studies 
to date have reported whether pinworm or other infectious stimuli can have a similar protective 
effect in B-ALL.  Several studies, on the other hand, support the predominate theory that TA 
coordinates with infectious exposures to drive leukemogenesis, therefore we suspected that 
pinworm exposed TA Cdkn2a-/- mice might have had an increased incidence and decreased 
latency of leukemia/lymphoma development relative to pinworm-free mice in our fenbendazole-
treated SPF facility.   
Our intentional pinworm-exposure experiment did not include SPF-facility control mice, 
therefore we used historical data to compare the development of leukemia/lymphoma in pinworm 
infected vs. SPF conditions.  Specifically, we combined data from the cohorts of pinworm-exposed 
TA Cdkn2a-/- and Cdkn2a-/- mice from 2018-2019 (Figure 4.2E) with the cohorts of genotype-
matched mice housed in our SPF facility during the pinworm outbreak (Figure 4.2B).  We also 
combined the datasets of TA Cdkn2a-/- and Cdkn2a-/- mice from independent experiments of post-
Fenbendazole survival studies conducted in the pinworm-eradicated SPF facility from 2015-2017 
(Figures 4.2C and D).  Cancer and leukemia/lymphoma development were analyzed in the 
combined datasets. As expected, pinworm exposure caused TA Cdkn2a-/- mice to develop cancer 
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faster than SPF-housed TA Cdkn2a-/- mice (Gehan-Breslow-Wilcoxon p=0.013, Figure 4.3A and 
Table 4.2) and increased cancer incidence from 76% to 93% (Chi-square p=0.01, Table 4.1). The 
median latency to cancer was 202 days in pinworm exposed TA Cdkn2a-/- mice and 248 days in 
SPF-housed TA Cdkn2a-/- mice. In regards to Cdkn2a-/- mice, pinworm exposure had the opposite 
effect of slowing cancer development (median cancer free survival for pinworm Cdkn2a-/- vs SPF 
Cdkn2a-/- 259 vs 218 days, Gehan-Breslow-Wilcoxon p=0.033, Figure 4.3B). When all 4 curves 
were overlaid, the most apparent difference was observed between pinworm exposed TA 
Cdkn2a-/- and Cdkn2a-/- mice. Of note, although we observed changes in time to disease, there 
was no observed impact of pinworm on cancer incidence in Cdkn2a-/- mice, whether or not they 
expressed TA.  These results identified pinworm as a specific infectious exposure that may have 
a dual capacity for protecting against or promoting cancer depending on the presence or absence 
of TA.   
We then aimed to determine whether pinworm exposure had a similar bi-directional effect 
specifically on leukemia/lymphoma development in TA Cdkn2a-/- and Cdkn2a-/- mice.  Contrary to 
our expectation, pinworm exposure did not impact the incidence of leukemia/lymphoma in TA 
Cdkn2a-/- mice.  In fact, the 52% incidence of leukemia/lymphoma in pinworm-exposed TA 
Cdkn2a-/- mice was strikingly similar to the 51% incidence in pinworm-free SPF TA Cdkn2a-/- mice 
(Table 4.1).  Survival curves provided further support for the lack of a leukemogenic effect of 
pinworm in TA Cdkn2a-/- mice (Figure 4.3D). The pinworm-exposed Cdkn2a-/- curve was shifted 
slightly to the right of the SPF Cdkn2a-/- cohort (Figure 4.3E). The median survival for 
pinworm-exposed Cdkn2a-/- mice increased to 365 days from the 305 day median survival for 
SPF-housed Cdkn2a-/- mice (Table 4.2), but this difference did not reach statistical significance.  
Although pinworm exposure only yielded a modest impact on leukemia/lymphoma development 
in TA Cdkn2a-/- and Cdkn2a-/- mice, the cumulative bi-directional effect of pinworm resulted in a 
significant difference between these two mouse strains that was not observed under SPF 
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conditions (Figure 4.3F).  Overall our results suggest that, in the absence of TA, pinworm slows 
the development leukemia/lymphoma.  
 
4.3 DISCUSSION 
 
Our data demonstrate that low IL-10 levels indirectly promote the production of 
myeloid-associated pro-inflammatory cytokines and drive bone marrow B cell DNA damage by 
perpetuating a state of microbial dysbiosis. These results provide additional support for the 
hypothesis that early disruptions in microbiome development can increase the risk of ALL by 
predisposing children to aberrant responses to infection. Events that restrict early microbial 
exposures in newborns, such as elective cesarean birth and limited breastfeeding, are 
associated with an increased risk of childhood ALL86–88. In contrast, IL-10 deficiency, also 
associated with increased ALL risk, is known to elevate levels of particular bacterial species in 
the intestine89,90. It is possible that these seemingly divergent effects might in fact both increase 
ALL risk by disrupting the normal composition of the intestinal microbiome. As microbial 
composition can influence the type and severity of childhood infections91,92, a valuable future 
direction would be to delineate which microbial communities may be associated with childhood 
leukemia by sequencing bacteria in fecal samples from human neonates or pre-leukemic mice. 
Moreover, prenatal and postnatal antibiotic treatment can drastically impact the infant 
microbiome93. Therefore, analysis of maternal and childhood antibiotic treatment records could 
provide key insight into the relationship between microbial dysbiosis and ALL risk.   
Upregulation of TLR signaling is a key pathway by which microbial dysbiosis promotes 
lymphoid malignancies.  H. pylori-derived LPS promotes gastric tumors and Mucosa-associated 
lymphoid tissue (MALT) lymphomas by stimulating proliferation and AID-associated 
mutagenesis of gastric epithelial cells and mature B cells.  Given that TLR4 signaling can be 
negatively regulated by IL-1094, it is possible that the loss of IL-10 may serve as an indirect 
source of TLR4 activation that contributes to B-ALL initiation in mice.  Evidence from prior 
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animal studies on B-ALL pathogenesis suggests that TLR4 stimulation may require additional 
environmental cues in order to transform immature B cells95–97.  Decreased IL-7 signaling is an 
example of one possible environmental cue that could play a critical role in the infectious 
etiology of B-ALL. Others have reported that IL-7 withdrawal, when combined with LPS 
stimulation, can trigger the concurrent activation of RAG and AID enzymes, leading to in vitro 
mutagenesis of TA B cells and in vivo initiation B-ALL in mice8.  Additionally, IL-10 loss results in 
drastic upregulation of G-CSF, a potent inhibitor of stromal cell-derived IL-7.  Based on these 
findings, it is interesting to consider that IL-10 deficiency may promote the development of 
pediatric B-ALL by influencing multiple B cell pathways, including those that involve TLR4 and 
IL-7 signaling.  
Others have shown that TLRs can suppress the growth of pre-leukemic B cells and 
delay leukemogenesis64. Notably, studies showing a protective role of TLR agonists in B-ALL 
were conducted in the absence of chronic inflammation. Furthermore, IL-10 is a major 
downstream target of several TLRs98–102. Therefore, it is likely that TLRs play a dual role, either 
protective or pathogenic, in B-ALL development depending on the presence of coordinating 
environmental cues. An interesting future direction would be to dissect how TLR ligands in the 
presence and absence of inflammation impact mutagenesis and survival signaling pathways in 
immature B cells. 
Our results also demonstrate that pinworm exposure slightly delays the development of 
leukemia/lymphoma in Cdkn2a-/- mice. Pinworm-microbiome interactions can be effective in 
driving the production of IL-10 and other Th2 cytokines103,104. Therefore, interventions that elicit 
similar Th2 or immunosuppressive responses may benefit children born with a high risk of 
developing B-ALL. Notably, the incidence of leukemia/lymphoma was not decreased by 
pinworm, which was unexpected considering the historical context of increased B-ALL incidence 
in the developed world105–107. This may reflect a different window of disease susceptibility 
between our mouse model and humans. Several reports have described a peak in the incidence 
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of childhood ALL between the ages of two and five108. This finding led to the idea that children 
are most vulnerable to ALL during a window of susceptibility that ranges from in utero 
development to the early years of life. Although the molecular characteristics of B-ALL in 
Cdkn2a-/- mice closely resemble that of human B-ALL, the timing of B-ALL onset coincides with 
murine adulthood and does not reflect an early-life window of susceptibility23,109.  For this 
reason, pinworm exposure may have different protective outcomes in humans and mice 
depending on the timing of mutagenic events relative to the window of susceptibility. In regard to 
our survival study, it is possible that pinworm shifts the timing of mutagenic events so that they 
are delayed, but still able to occur within the window of susceptibility. This could explain why 
pinworm exposure increased the latency of leukemia/lymphoma in Cdkn2a-/- mice, without 
decreasing its incidence. If the window of susceptibility to ALL is more restricted in humans than 
in Cdkn2a-/- mice, it is possible that a pinworm-induced mutagenic delay in humans may cause 
the window of susceptibility to be completely missed, thereby decreasing the risk of ALL.  Future 
analysis in humans, and in refined mouse models of B-ALL that more closely match the timing 
of human disease, will be required to delineate how the timing and type of early childhood 
parasite-microbiota interactions may influence ALL incidence. 
The mutational status of pre-leukemic cells may also influence the effect of pinworm 
exposure on leukemia/lymphoma development.  Interestingly, the protective effect of pinworm 
on suppressing leukemia/lymphoma in Cdkn2a-/- mice did not apply to TA positive Cdkn2a-/- 
mice, suggesting that TA blocks pinworm-mediated protection.  This may reflect the previously 
described ability of TA to increase the responsiveness of pre-leukemic B cells to environmental 
exposures8,9,23,110, thereby lowering the threshold for an inflammatory response to promote 
B-ALL.  Despite the influence of pinworm infection on the acquisition of normal gut microbiota 
and Th2 immunity, hosts are still susceptible to infection and inflammation from other 
sources111.  It is possible that normal levels of immune stimulation in the context of infection may 
be sufficient to elicit a proliferative or mutagenic response in TA+ B cell clones.  Alternatively, 
 64 
pre-leukemic TA+ B cells may be resistant to pinworm-mediated immunosuppression.  It is well 
established that TA can coordinate with radiation, chemicals, and infectious exposures to drive 
lymphoid malignancies8,9,23,110, however the potential for TA, or another initiating lesion, to 
interfere with protective exposures has not been fully explored.  Thus, future studies are 
warranted to investigate the antagonistic effect of TA expression on pinworm-mediated 
protection in leukemia/lymphoma.  Treatments that simulate the downstream effects of pinworm 
exposure on microbe-immune cell interactions may be an ideal intervention for neonates with a 
high-risk of developing ALL.  Collectively, our data demonstrate that the Th2 immune response 
could be a suppressor of leukemia/lymphoma development.  In the absence of IL-10, a key 
regulator of Th2 immunity, microbial dysbiosis may trigger an innate immune response that is 
associated with B cell DNA damage and leukemogenesis.  Conversely, exposing TA negative 
mice to pinworm, a well-established stimulator of Th2 immunity, protects against 
leukemia/lymphoma.  Fostering the development of Th2 immunity, particularly in children born 
with low IL-10 levels, may be an important approach in the prevention and treatment of 
childhood ALL. 
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4.4 FIGURES 
 
 
 
 
Figure 4.1. Antibiotic treatment response rescues Il10-/- Ckdn2a-/- B cells from impaired 
development and DNA damage. 
(A) Schematic diagram of antibiotic treatment and tracking of peripheral blood and bone marrow 
cells in adult mice.  (B) Concentration of cytokines in Il10-/- Cdkn2a-/- mice and controls. Lines 
connect values from the same mouse sampled before and after antibiotic treatment (ABX).  
Two-tailed paired t-test. (C) Flow analysis of percent CD11b+ cells and CD19+ B220+ cells of 
bone marrow, and percent gH2AX+ of CD19+ B220+ cells in Cdkn2a-/- and Il10-/- Cdkn2a-/- mice 
treatment with placebo (-) or antibiotics (+) for 4 weeks. Bar shows mean, Mann-Whitney U-test.  *p ≤ 0.05, **p ≤ 0.01. 
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Figure 4.2. TA Cdkn2a-/- and Cdkn2a-/- differ in leukemia/lymphoma development in the 
presence of pinworm. 
(A) Timeline of individual survival studies following Cdkn2a-/- and TA Ckdn2a-/- mice in SPF and 
Conventional facilities relative to the 2013 fenbendazole treatment.  (B) Representative survival 
curves of leukemia/lymphoma development in Cdkn2a-/- (n=34) and TA Cdkn2a-/- (n=22) mice 
housed in an SPF facility during a pinworm outbreak prior to fenbendazole treatment (p=0.001).  
Arrows follow chronological order of survival studies.  The year in brackets corresponds to the 
euthanasia date of the last mouse to develop illness in each cohort.  (C-D) Survival curves from 
two independent experiments of mice housed in an SPF facility after pinworm was eradicated 
with fenbendazole treatment. 2016-2017: Cdkn2a-/- (n=58) and TA Cdkn2a-/- (n=40) (p=0.236); 
2017: Cdkn2a-/- (n=18) and TA Cdkn2a-/- (n=15) (p=0.941).  (E) Survival curve from one 
experiment in which Cdkn2a-/- (n=20) and TA Cdkn2a-/- (n=22) mice were housed in an SPF 
facility for 4 weeks, then transferred to a conventional facility for exposure to pinworm bedding 
(p=0.058).  Gehan-Breslow-Wilcoxon test was applied to survival curves. 
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Figure 4.3. The capacity of pinworm to protect against or promote cancer in Cdkn2a-/- 
mice depends on TEL-AML1 status. 
Cumulative survival curves showing combined data from cohorts in Figures 4B-E. Cancer free 
survival for SPF and pinworm-exposed (A) Cdkn2a-/- TA+ mice, (B) Cdkn2a-/- mice, and (C) all 
strains. Leukemia/lymphoma free survival for SPF and pinworm-exposed (D) Cdkn2a-/- TA+ 
mice, (E) Cdkn2a-/- mice, and (F) all strains. SPF TA Cdkn2a-/- mice (n=55, filled orange 
squares), pinworm-exposed TA Cdkn2a-/-mice (n=44, open orange squares), SPF Cdkn2a-/-mice 
(n=76, filled black triangles), pinworm-exposed Cdkn2a-/-mice (n=54, open black triangles. 
Gehan-Breslow-Wilcoxon test was applied to survival curves. 
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4.5 TABLES 
 
Table 4.1. Disease outcomes in Ckdn2a-/- and TA Ckdn2a-/- mice housed in a SPF facility 
or pinworm-infected conventional facility 
 
 
SFP Cdkn2a -/- 
(N=76)
SFP TA Cdkn2a-/-  
(N=55)
Pinworm Cdkn2a -/- 
(N=54)
Pinworm TA Cdkn2a -/- 
(N=44)
Cancer 56 (74%) 42 (76%) 44 (81%) 41 (93%)
     Leukemia/Lymphoma 23 (30%) 28 (51%) 14 (26%) 23 (52%)
Table 4.1 Disease outcomes in Cdkn2a -/- and TA Cdkn2a -/- mice housed in a SFP or a pinworm-infected conventional 
facility
N (% total)
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Table 4.2. Median cancer latency of Ckdn2a-/- and TA Ckdn2a-/- mice housed in a SPF 
facility or pinworm-infected conventional facility 
 
 
SFP Cdkn2a -/- 
(N=96)
SFP TA Cdkn2a-/-  
(N=68)
Pinworm Cdkn2a -/- 
(N=56)
Pinworm TA Cdkn2a -/- 
(N=44)
Cancer 218 248 259 202
     Leukemia/Lymphoma 305 253 365 231
Table 4.2 Median cancer latency of Cdkn2a -/- and TA Cdkn2a -/- mice housed in a SFP facility or pinworm-
infected conventional facility
Median latency (days)
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CHAPTER 5: CONCLUDING REMARKS 
 
 CONTRIBUTIONS TO THE FIELD OF B-ALL ETIOLOGY 
 
Research conducted over the past century has suggested that pediatric B-ALL may be a 
preventable cancer.   In recent years, numerous studies have provided evidence that immune 
dysfunction can drive ALL by coordinating with underlying genetic abnormalities5.  These results 
led to proposals that vaccinations, probiotics, and synbiotics could prevent some cases of B-
ALL by supporting the development of the neonatal immune system5,59.  A challenge that the 
field now faces is to determine what type of immune responses should be promoted and which 
individuals have a high enough risk to be treated for prevention.   This dissertation makes three 
insightful contributions to the above question by (1) identifying parasitic infection as protective 
against B-ALL, (2) providing evidence for IL-10 deficiency as a B-ALL risk factor, and (3) 
presenting a mechanism that describes how the microbial dysbiosis may serve as a 
convergence point for infectious stimuli in B-ALL pathogenesis. 
5.1 PROTECTIVE EFFECT OF PARASITIC INFECTIONS IN B CELL 
LEUKEMIA/LYMPHOMA 
 
  Although the protective role of early childhood infections is a fundamental principle of 
the delayed infection hypothesis, no studies to date have demonstrated a causal role for 
infections in protection against B-ALL.  Others have shown that treatment with synthetic CPG, a 
TLR9 agonist, can delay leukemogenesis in the Eμ-ret mouse model of B-ALL64.  However, 
evidence supporting a role of infections in impairing the progression of leukemia was lacking. By 
demonstrating that pinworm infection slows the latency of leukemia/lymphoma in Cdkn2a-/- 
mice, our study is the first to demonstrate that pathogenic infections can have an inhibitory 
effect in leukemogenesis.    
 
A remaining question is why pinworm infection demonstrated a protective effect, 
whereas other infectious exposures have been reported to promote B-ALL in mice. There is a 
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substantial gap of knowledge regarding the type of infections or inflammatory responses that 
impact B-ALL.  Several epidemiology groups have noted a lack of evidence implicating a 
particular infectious pathogen in childhood leukemia development, and have instead suggested 
that impaired Th2 immunity or excessive Th1/Th17 responses may promote the development of 
childhood hematological malignancies.  Our observation that pinworm exposure delays the 
latency of leukemia/lymphoma provides additional support for the protective role of Th2 
immunity in childhood leukemia.  Th2 immune responses to helminth infection have long been 
associated with suppression of autoimmunity and allergic disease. In fact, several studies have 
reported that pinworm infections often stimulate an IL-10 associated Th2 response in host 
mice112.  A limitation of the current study was that we did not measure which cytokines were 
produced in response to pinworm-exposure. Future investigations could benefit from confirming 
that pinworm infection in our conventional facility stimulates a Th2 response in Cdkn2a-/- mice. 
Additional insight could be gained by determining whether other infectious pathogens that 
stimulate Th2 immune responses also have the capacity to delay leukemogenesis in the 
Cdkn2a-/- mouse model. 
This work also provided new insight on the interaction between pinworm exposure and 
genetic lesions during the development of leukemia/lymphoma.  Although pinworm exposure 
delayed leukemia/lymphoma development in Cdkn2a-/- mice, we did not detect a protective 
effect in Cdkn2a-/- mice that expressed TEL-AML1.  This novel finding suggests that the benefit 
of using infectious exposures to suppress leukemia may be limited to children who lack specific 
genetic lesions.  The implication of this result for preventive therapy development is that early 
immune stimulation alone may be insufficient to protect against leukemia in a subset of children.  
Therefore, developing combinational therapies that target both immune system development 
and genetic mutations could be a valuable future endeavor.   
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5.2 IL-10 DEFICIENCY DRIVES B CELL LEUKEMIA/LYMPHOMA 
 
In addition to demonstrating a protective effect of Th2-associated infectious exposures, 
we showed that the absence of IL-10, a key regulator of Th2 response, accelerates the 
development of leukemia/lymphoma in TA+ Cdkn2a-/- mice.  This finding builds upon the 
observation that low levels of IL-10 in neonates is associated with an increased risk of childhood 
ALL11.  Of note, there was a surprising inconsistency between the epidemiological and mouse 
studies. In the human study, the risk of developing ALL was increased by low IL-10 levels. In 
mice, we found that leukemia/lymphoma latency, but not risk, was impacted by decreased IL-10. 
A possible explanation for this observation is that the relatively high incidence of 
leukemia/lymphoma in the TA+ Cdkn2a-/- model may limit the detection of changes in disease 
incidence.  Therefore, a different mouse model with a lower incidence of leukemia/lymphoma 
may be better suited for future studies aimed at addressing whether low levels of IL-10, or other 
immune system manipulations, have an impact on the risk of developing ALL. 
In addition to supporting a causal role of low IL-10 levels in B cell leukemia/lymphoma 
development, we characterized a set of pro-inflammatory cytokines, including G-CSF, IL-6, and 
IL-17, that are associated with DNA damage in bone marrow precursor B cells. Our finding that 
B cell gH2AX levels were not elevated in the absence of myeloid inflammation highlighted the 
potential role of inflammation in inducing B cell DNA damage in Il10-/- mice. Notably, 
inflammation in Il10-/- mice was also associated with a severe B cell suppression.  This raises 
the possibility that the decrease in B-cells and the increase in double-strand breaks have a yet 
undelineated connection in their causality.  This interpretation is supported by in vitro studies 
which showed the importance of IL-7 withdrawal and TGF-b, well-established inhibitors of B cell 
growth, in inducing DNA damage in human B cells5,8.  Whether an in vivo innate inflammatory 
response acts through a common mechanism of DNA mutagenesis has yet to be determined.  
Future work should focus on identifying which inflammatory cytokines in Il10-/- mice are 
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necessary for inducing B cell DNA damage and leukemogenesis. This work may ultimately aid 
in compiling a panel of cells and cytokines that can be measured at birth and during early 
childhood infections to predict ALL risk. 
5.3 MECHANISM FOR MICROBIAL-INDUCED INFLAMMATION IN CHILDHOOD B CELL 
MALIGNANCIES 
 
Numerous epidemiological studies from past decades have supported there being a role 
of insufficient microbial exposures in promoting childhood leukemia5,59. A few recent studies 
have revealed that newborns delivered through cesarean section or breastfed either not at all or 
for only a short period of time have a significantly increased risk of developing leukemia during 
childhood86–88,113. Little is known about how the composition of the neonatal microbiome effects 
B cell transformation in distal microenvironments such as the bone marrow. However, evidence 
exists that gut bacteria can induce VDJ recombination in B cells within the lamina propria81. We 
used antibiotics to demonstrate that suppressing microbial dysbiosis in Il10-/- mice can reduce 
DNA damage in bone marrow B cells. Although we did not assess the impact of antibiotics on 
leukemia/lymphoma development, we found that pinworm exposure and wild-type IL-10 
expression, both of which promote microbial homeostasis, protect against B cell disease in 
mice. These data are the first to provide evidence that microbial dysbiosis can contribute to B 
cell DNA damage in the bone marrow.  Overall, these data support a mechanism in which low 
IL-10 levels promote the development childhood of B cell leukemia/lymphoma by disrupting the 
control of pathogenic inflammation by the gut microbiome (Figure 5.1). Helminth infections that 
induce microbial-mediated immunosuppression via IL-10, may have the opposite effect of 
protecting against leukemia. 
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5.4 FIGURES 
 
 
 
Figure 5.1. Model for the role of microbial dysbiosis in childhood B cell 
leukemia/lymphoma. 
IL-10 deficiency induces microbial dysbiosis in the gut, resulting in inflammation with distal 
effects of granulopoieis, B cell deficiency, and B cell DNA damage in the bone marrow.  The 
inflammation-associated acquisition of genetic lesions in bone marrow pro-B and IgM+ B cells 
leads to the development of B cell leukemia/lymphoma.  Antibiotics may counteract the impact 
of low IL-10 by restoring bacterial homeostasis in the gut. Pinworm also counteracts microbial 
dysbiosis by increasing the production of Th2 related cytokines, such as IL-10. 
Low IL-10
Microbial Dysbiosis
Inflammation
BM Granulopoiesis B cell deficiency
B cell DNA damage
B cell leukemia/lymphoma
Pinworm
Antibiotics
High IL-10
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CHAPTER 6: MATERIALS AND METHODS 
 
Mice 
B6.129P2-Il10tm1Cgn/J mice (referred to in the text as Il10-/- mice, MGI: 1857199 Jackson 
Laboratory: 002251) were purchased from The Jackson Laboratory and then crossed >10 
generations into the FVB/n strain background.  Control FVB/n mice were bred in house.   
Cre+ TA+ Cdkn2a-/- mice have been previously described and were maintained on the FVB/n 
strain background.  B6.129 Il10-/- mice had been crossed to Cre+ TA+ Cdkn2a-/- mice on the 
FVB/n background for 4 generations.  All experiments were performed following institutional 
review and approval by the UCSF Institutional Animal Care and Use Committee. 
 
Cytokine Analyses 
For peripheral blood plasma, whole blood was obtained through submandibular bleeding, 
collected in EDTA-coated tubes (Becton Dickinson), and centrifuged for 10 minutes at 1,600 x g 
at 4°C to remove blood cells.  Complete blood count analyses were performed using a Hemavet 
haematology system (Drew Scientific).  The supernatant was assayed in duplicate.  A total of 32 
cytokines were measured (Table 1) using 9-plex (IL-15, IL-18, Basic FGF, LIF, M-CSF, MIG, 
MIP-2, PDGF-BB, and VEGF) and 23-plex (IL-1a, IL1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, 
IL12p40, IL-12p70, IL-13, IL-17A, Eotaxin, G-CSF, GM-CSF, IFN-r, KC, MCP-1, MIP-1a, MIP-
1B, RANTES, and TNF-a) luminex bead-based assays (Bio-Rad).  Protein content of each extract 
was determined with the Bradford Assay (Bio-Rad).  Cytokine measurements for each duplicate 
were averaged and normalized to protein concentrations. 
 
Isolation of immune cells 
For bone marrow cells, the four long bones (two femur and two tibiae) of the same mice were 
flushed with FACS buffer (Hank’s balanced salt solution Ca2+/Mg2+ free, 2% heat-inactivated fetal 
bovine serum, 2.5% cell dissociation buffer, penicillin/streptomycin).  Spleens and mesenteric lymph 
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nodes were physically dissociated in FACS buffer.  Cell suspensions were filtered through a 70µm 
strainer.  Mononuclear cells and granulocytes were collected after centrifugation of filtered 
suspensions on Histopaque 1119 (Sigma #11191).  Whole peripheral blood was collected in EDTA 
tubes and incubated in ACK red blood cell lysis buffer immediately or after plasma depletion.   
 
Cell staining and flow cytometry 
Cell viability was measured before flow cytometry using Trypan Blue and tracked during flow 
cytometry using DAPI or Ghost dye Violet 450 viability dye.  After viability staining, cells were 
blocked in FcBlock or Rat IgG for 10 minutes in the dark on ice.  Without washing, primary surface 
staining antibodies were added for an additional 20 minutes.  Cells stained with biotinylated surface 
antibodies were then stained with fluorochrome-labeled streptavidin for 20 minutes.  For intracellular 
staining, EGFP signal was preserved by fixing cells in 4% Formaldehyde for 15 minutes at room 
temperature in the dark.  Additional fixation and permeabilization was done using the BD 
Cytofix/Cytoperm kit per manufacturer’s instructions.  Cells from transplantation recipients were 
analyzed on a FACSCalibur (Becton Dickinson).  All other flow cytometry analysis was acquired 
using a SP 6800 Spectral Analyzer (Sony Biotechnology).  Antibody information, including clones 
and dilutions, is listed in listed in Table S2. 
 
Apoptosis assay 
After surface antibody staining, CellEvent Caspase-3/7 Green Detection Reagent (Invitrogen) was 
added to cells according to the manufacturer’s instructions.  DAPI was added to stain dead cells and 
the percentage of DAPI- CellEvent Caspase-3/7+ cells was assessed by flow cytometry. 
 
Proliferation assay 
Mice were injected i.p.  with 100µl (10mg/mL) BrdU and euthanized 1 hour later.  Cells were first 
stained for surface markers and then processed according to the FITC BrdU Flow Staining Protocol 
(BD Pharmingen).   
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Transplantation  
8-16 week-old FVB/n and Il10-/- recipient mice were sublethally irradiated with a split dose of 
irradiation (10Gy for FVB/n mice and 8-8.5Gy for Il10-/- mice) 4-5 hours apart from a Cs137 
source (J.L.  Shepherd).  Irradiated recipients were injected retro-orbitally with 2 x 10^6 bone 
marrow cells from 5-6 week-old Cre+ TA+ Cdkn2a-/- or Il10-/- Cre+ TA+ Cdkn2a-/- mice.  Transplant 
recipients were administered antibiotics following transplantation and analyzed for donor-
derived EGFP+ chimerism by regular bleeding.   
 
Antibiotic treatment 
Nutritionally complete pellets containing Amoxicillin, Clarithromycin, Metronidazole and 
Omeprazole (Bio-Serv) were provided to mice.  These antibiotics are effective against a broad 
spectrum of Helicobacter strains.   
 
Pathological Analyses 
At the time of euthanasia, a gross necropsy was performed to identify potential sources of 
illness and selected tissues were placed into buffered formalin.  If gross necropsy findings 
suggested a hematopoietic neoplasm, single cell suspensions of involved tissues were prepared 
when possible and cryopreserved in medium containing 10% DMSO.  Formalin Fixed Paraffin 
Embedded (FFPE) tissues were stained with hematoxylin & eosin.  Diagnoses were based upon 
gross necropsy and histopathology.  Additional diagnostic information was obtained by 
immunophenotyping when necessary. 
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DNA extraction 
The DNeasy and QIAamp DNA FFPE Tissue kits (Qiagen) were used to extract DNA from 
cryopreserved or FFPE samples from leukemic mice.  DNA concentration and quality were 
determined by Nanodrop spectrophotometry and PicoGreen (Invitrogen). 
 
Whole Exome Sequencing 
DNA samples were submitted to MedGenome for mouse exome capture and sequencing.  DNA 
sequencing libraries were prepared using the SureSelectXT Mouse All Exon Kit (Agilent) 
according to the manufacturer’s instructions.  Samples were sequenced with paired-end 100-bp 
reads on an Illumina HiSeq2500.  The resulting reads in .bam files were aligned to the 
GRCm38/mm10 M.  musculus genome reference using BWA.  Genome Analysis Toolkit 
(GATK) was used to recalibrate base quality score and realign reads around insertions and 
deletions (indels).  Alignment and coverage metrics were collected using Picard.  SNVs were 
called using Mutect version 1.1.4, a somatic variant detection program.  Each tumor was called 
against a panel of normal tails and spleens from this experiment.  Calls were filtered against a 
database of known M.  Musculus germline single-nucleotide polymorphisms.  Results were 
further filtered to calls with a minimum read depth of 10 and a minimum mutant allele fraction of 
10%.  Variants were annotated using Annovar and mutations present in human cancers were 
identified using the COSMIC database. 
 
Statistical Analysis 
Pairwise statistical significance was evaluated by two-tailed Mann-Whitney U-test or Student’s 
t-test.  Correlations were calculated using the Spearman correlation.  Survival analyses were 
performed using GraphPad Prism software.  In previous survival analyses for Cdkn2a-/- mice, 
irradiation was associated with early disease development23.  Given that the mice in the current 
 79 
study are derivatives of Cdkn2a-/- mice, we chose to use the Gehan-Breslow-Wilcoxon test, 
which is the most sensitive and appropriate test for detecting early shifts in survival. 
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